Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:antileukemic agent'
(id=6888040 ; fe=en:antileukemic agent ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=18783 creation date=2017-06-25 touchdate=2025-07-25 10:50:19.000)
≈ 506 relations sortantes

  1. en:antileukemic agent -- r_associated #0: 43 / 1 -> en:streptozocin
    n1=en:antileukemic agent | n2=en:streptozocin | rel=r_associated | relid=0 | w=43
  2. en:antileukemic agent -- r_associated #0: 42 / 0.977 -> en:aromatase inhibitor
    n1=en:antileukemic agent | n2=en:aromatase inhibitor | rel=r_associated | relid=0 | w=42
  3. en:antileukemic agent -- r_associated #0: 42 / 0.977 -> en:factor viia inhibitor pci-27483
    n1=en:antileukemic agent | n2=en:factor viia inhibitor pci-27483 | rel=r_associated | relid=0 | w=42
  4. en:antileukemic agent -- r_associated #0: 42 / 0.977 -> en:galectin-1 inhibitor otx008
    n1=en:antileukemic agent | n2=en:galectin-1 inhibitor otx008 | rel=r_associated | relid=0 | w=42
  5. en:antileukemic agent -- r_associated #0: 42 / 0.977 -> en:mcl-1 inhibitor amg 176
    n1=en:antileukemic agent | n2=en:mcl-1 inhibitor amg 176 | rel=r_associated | relid=0 | w=42
  6. en:antileukemic agent -- r_associated #0: 41 / 0.953 -> en:cannabidiol
    n1=en:antileukemic agent | n2=en:cannabidiol | rel=r_associated | relid=0 | w=41
  7. en:antileukemic agent -- r_associated #0: 40 / 0.93 -> en:fermented soybean protein beverage
    n1=en:antileukemic agent | n2=en:fermented soybean protein beverage | rel=r_associated | relid=0 | w=40
  8. en:antileukemic agent -- r_associated #0: 40 / 0.93 -> en:protective agent
    n1=en:antileukemic agent | n2=en:protective agent | rel=r_associated | relid=0 | w=40
  9. en:antileukemic agent -- r_associated #0: 39 / 0.907 -> en:epipropidine
    n1=en:antileukemic agent | n2=en:epipropidine | rel=r_associated | relid=0 | w=39
  10. en:antileukemic agent -- r_associated #0: 39 / 0.907 -> en:paclitaxel
    n1=en:antileukemic agent | n2=en:paclitaxel | rel=r_associated | relid=0 | w=39
  11. en:antileukemic agent -- r_associated #0: 38 / 0.884 -> en:cebpa-targeting sarna mtl-cebpa liposome
    n1=en:antileukemic agent | n2=en:cebpa-targeting sarna mtl-cebpa liposome | rel=r_associated | relid=0 | w=38
  12. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:ceritinib
    n1=en:antileukemic agent | n2=en:ceritinib | rel=r_associated | relid=0 | w=37
  13. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:cladribine
    n1=en:antileukemic agent | n2=en:cladribine | rel=r_associated | relid=0 | w=37
  14. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:cytoprotective agent
    n1=en:antileukemic agent | n2=en:cytoprotective agent | rel=r_associated | relid=0 | w=37
  15. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:mdm2 inhibitor ds-3032b
    n1=en:antileukemic agent | n2=en:mdm2 inhibitor ds-3032b | rel=r_associated | relid=0 | w=37
  16. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:tasisulam sodium
    n1=en:antileukemic agent | n2=en:tasisulam sodium | rel=r_associated | relid=0 | w=37
  17. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:thioguanine
    n1=en:antileukemic agent | n2=en:thioguanine | rel=r_associated | relid=0 | w=37
  18. en:antileukemic agent -- r_associated #0: 37 / 0.86 -> en:topoisomerase-ii inhibitor
    n1=en:antileukemic agent | n2=en:topoisomerase-ii inhibitor | rel=r_associated | relid=0 | w=37
  19. en:antileukemic agent -- r_associated #0: 36 / 0.837 -> en:ambazone
    n1=en:antileukemic agent | n2=en:ambazone | rel=r_associated | relid=0 | w=36
  20. en:antileukemic agent -- r_associated #0: 36 / 0.837 -> en:antagonist
    n1=en:antileukemic agent | n2=en:antagonist | rel=r_associated | relid=0 | w=36
  21. en:antileukemic agent -- r_associated #0: 36 / 0.837 -> en:atr-101
    n1=en:antileukemic agent | n2=en:atr-101 | rel=r_associated | relid=0 | w=36
  22. en:antileukemic agent -- r_associated #0: 36 / 0.837 -> en:bet inhibitor
    n1=en:antileukemic agent | n2=en:bet inhibitor | rel=r_associated | relid=0 | w=36
  23. en:antileukemic agent -- r_associated #0: 36 / 0.837 -> en:breflate
    n1=en:antileukemic agent | n2=en:breflate | rel=r_associated | relid=0 | w=36
  24. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:abarelix
    n1=en:antileukemic agent | n2=en:abarelix | rel=r_associated | relid=0 | w=35
  25. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:acivicin
    n1=en:antileukemic agent | n2=en:acivicin | rel=r_associated | relid=0 | w=35
  26. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:alemtuzumab
    n1=en:antileukemic agent | n2=en:alemtuzumab | rel=r_associated | relid=0 | w=35
  27. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:angiogenesis inhibitor
    n1=en:antileukemic agent | n2=en:angiogenesis inhibitor | rel=r_associated | relid=0 | w=35
  28. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:antiapoptotic agent
    n1=en:antileukemic agent | n2=en:antiapoptotic agent | rel=r_associated | relid=0 | w=35
  29. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:antimetabolite chemotherapy
    n1=en:antileukemic agent | n2=en:antimetabolite chemotherapy | rel=r_associated | relid=0 | w=35
  30. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:antineoplastic agent trx-818
    n1=en:antileukemic agent | n2=en:antineoplastic agent trx-818 | rel=r_associated | relid=0 | w=35
  31. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:antineoplastic vinca alkaloid
    n1=en:antileukemic agent | n2=en:antineoplastic vinca alkaloid | rel=r_associated | relid=0 | w=35
  32. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:aromatase inhibitors, 3rd generation
    n1=en:antileukemic agent | n2=en:aromatase inhibitors, 3rd generation | rel=r_associated | relid=0 | w=35
  33. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:asp9853
    n1=en:antileukemic agent | n2=en:asp9853 | rel=r_associated | relid=0 | w=35
  34. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:bexarotene
    n1=en:antileukemic agent | n2=en:bexarotene | rel=r_associated | relid=0 | w=35
  35. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:birinapant
    n1=en:antileukemic agent | n2=en:birinapant | rel=r_associated | relid=0 | w=35
  36. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:calusterone
    n1=en:antileukemic agent | n2=en:calusterone | rel=r_associated | relid=0 | w=35
  37. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:chk1 inhibitor gdc-0425
    n1=en:antileukemic agent | n2=en:chk1 inhibitor gdc-0425 | rel=r_associated | relid=0 | w=35
  38. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:cinobufagin
    n1=en:antileukemic agent | n2=en:cinobufagin | rel=r_associated | relid=0 | w=35
  39. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:disinfectant
    n1=en:antileukemic agent | n2=en:disinfectant | rel=r_associated | relid=0 | w=35
  40. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:giracodazole
    n1=en:antileukemic agent | n2=en:giracodazole | rel=r_associated | relid=0 | w=35
  41. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:hdm2 antagonist jnj-26854165
    n1=en:antileukemic agent | n2=en:hdm2 antagonist jnj-26854165 | rel=r_associated | relid=0 | w=35
  42. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:intiquinatine
    n1=en:antileukemic agent | n2=en:intiquinatine | rel=r_associated | relid=0 | w=35
  43. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:mechlorethamine
    n1=en:antileukemic agent | n2=en:mechlorethamine | rel=r_associated | relid=0 | w=35
  44. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:metabolite
    n1=en:antileukemic agent | n2=en:metabolite | rel=r_associated | relid=0 | w=35
  45. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:methoxyamine
    n1=en:antileukemic agent | n2=en:methoxyamine | rel=r_associated | relid=0 | w=35
  46. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:mitoquidone
    n1=en:antileukemic agent | n2=en:mitoquidone | rel=r_associated | relid=0 | w=35
  47. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:nilutamide
    n1=en:antileukemic agent | n2=en:nilutamide | rel=r_associated | relid=0 | w=35
  48. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:nintedanib
    n1=en:antileukemic agent | n2=en:nintedanib | rel=r_associated | relid=0 | w=35
  49. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:organic sulfone compound
    n1=en:antileukemic agent | n2=en:organic sulfone compound | rel=r_associated | relid=0 | w=35
  50. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:palbociclib
    n1=en:antileukemic agent | n2=en:palbociclib | rel=r_associated | relid=0 | w=35
  51. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:pembrolizumab
    n1=en:antileukemic agent | n2=en:pembrolizumab | rel=r_associated | relid=0 | w=35
  52. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:phosphaplatin pt-112
    n1=en:antileukemic agent | n2=en:phosphaplatin pt-112 | rel=r_associated | relid=0 | w=35
  53. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:procarbazine
    n1=en:antileukemic agent | n2=en:procarbazine | rel=r_associated | relid=0 | w=35
  54. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:recombinant ephb4-hsa fusion protein
    n1=en:antileukemic agent | n2=en:recombinant ephb4-hsa fusion protein | rel=r_associated | relid=0 | w=35
  55. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:sensitive anticancer agent
    n1=en:antileukemic agent | n2=en:sensitive anticancer agent | rel=r_associated | relid=0 | w=35
  56. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:smac mimetic gdc-0152
    n1=en:antileukemic agent | n2=en:smac mimetic gdc-0152 | rel=r_associated | relid=0 | w=35
  57. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:smac mimetic gdc-0917
    n1=en:antileukemic agent | n2=en:smac mimetic gdc-0917 | rel=r_associated | relid=0 | w=35
  58. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:tasisulam
    n1=en:antileukemic agent | n2=en:tasisulam | rel=r_associated | relid=0 | w=35
  59. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:topical betulinic acid
    n1=en:antileukemic agent | n2=en:topical betulinic acid | rel=r_associated | relid=0 | w=35
  60. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:transferrin receptor-targeted anti-rrm2 sirna calaa-01
    n1=en:antileukemic agent | n2=en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 | rel=r_associated | relid=0 | w=35
  61. en:antileukemic agent -- r_associated #0: 35 / 0.814 -> en:trastuzumab
    n1=en:antileukemic agent | n2=en:trastuzumab | rel=r_associated | relid=0 | w=35
  62. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:alectinib
    n1=en:antileukemic agent | n2=en:alectinib | rel=r_associated | relid=0 | w=34
  63. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:aminopterin
    n1=en:antileukemic agent | n2=en:aminopterin | rel=r_associated | relid=0 | w=34
  64. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:amsacrine
    n1=en:antileukemic agent | n2=en:amsacrine | rel=r_associated | relid=0 | w=34
  65. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:anti-ksp/anti-vegf sirnas aln-vsp02
    n1=en:antileukemic agent | n2=en:anti-ksp/anti-vegf sirnas aln-vsp02 | rel=r_associated | relid=0 | w=34
  66. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:anti-nucleolin aptamer as1411
    n1=en:antileukemic agent | n2=en:anti-nucleolin aptamer as1411 | rel=r_associated | relid=0 | w=34
  67. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:anti-vegf anticalin prs-050-peg40
    n1=en:antileukemic agent | n2=en:anti-vegf anticalin prs-050-peg40 | rel=r_associated | relid=0 | w=34
  68. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:antiestrogen
    n1=en:antileukemic agent | n2=en:antiestrogen | rel=r_associated | relid=0 | w=34
  69. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:antineoplastic agents, phytogenic
    n1=en:antileukemic agent | n2=en:antineoplastic agents, phytogenic | rel=r_associated | relid=0 | w=34
  70. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:antineoplastic antibiotic
    n1=en:antileukemic agent | n2=en:antineoplastic antibiotic | rel=r_associated | relid=0 | w=34
  71. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:antineoplastic metal complex preparation
    n1=en:antileukemic agent | n2=en:antineoplastic metal complex preparation | rel=r_associated | relid=0 | w=34
  72. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:bcg vaccine
    n1=en:antileukemic agent | n2=en:bcg vaccine | rel=r_associated | relid=0 | w=34
  73. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:belinostat
    n1=en:antileukemic agent | n2=en:belinostat | rel=r_associated | relid=0 | w=34
  74. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:bevacizumab
    n1=en:antileukemic agent | n2=en:bevacizumab | rel=r_associated | relid=0 | w=34
  75. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:bicalutamide
    n1=en:antileukemic agent | n2=en:bicalutamide | rel=r_associated | relid=0 | w=34
  76. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:chlorotoxin [131i]
    n1=en:antileukemic agent | n2=en:chlorotoxin [131i] | rel=r_associated | relid=0 | w=34
  77. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:clanfenur
    n1=en:antileukemic agent | n2=en:clanfenur | rel=r_associated | relid=0 | w=34
  78. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:concomitant agent
    n1=en:antileukemic agent | n2=en:concomitant agent | rel=r_associated | relid=0 | w=34
  79. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:dihydrolenperone
    n1=en:antileukemic agent | n2=en:dihydrolenperone | rel=r_associated | relid=0 | w=34
  80. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:dimethyl sulfoxide
    n1=en:antileukemic agent | n2=en:dimethyl sulfoxide | rel=r_associated | relid=0 | w=34
  81. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:eflornithine
    n1=en:antileukemic agent | n2=en:eflornithine | rel=r_associated | relid=0 | w=34
  82. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:enzalutamide
    n1=en:antileukemic agent | n2=en:enzalutamide | rel=r_associated | relid=0 | w=34
  83. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:finished pharmaceutical product
    n1=en:antileukemic agent | n2=en:finished pharmaceutical product | rel=r_associated | relid=0 | w=34
  84. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:forodesine
    n1=en:antileukemic agent | n2=en:forodesine | rel=r_associated | relid=0 | w=34
  85. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:hypoxia-activated prodrug th-302
    n1=en:antileukemic agent | n2=en:hypoxia-activated prodrug th-302 | rel=r_associated | relid=0 | w=34
  86. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:inproquone
    n1=en:antileukemic agent | n2=en:inproquone | rel=r_associated | relid=0 | w=34
  87. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:intravesical bcg
    n1=en:antileukemic agent | n2=en:intravesical bcg | rel=r_associated | relid=0 | w=34
  88. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:kanglaite
    n1=en:antileukemic agent | n2=en:kanglaite | rel=r_associated | relid=0 | w=34
  89. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:lenalidomide
    n1=en:antileukemic agent | n2=en:lenalidomide | rel=r_associated | relid=0 | w=34
  90. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:medication
    n1=en:antileukemic agent | n2=en:medication | rel=r_associated | relid=0 | w=34
  91. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:naptumomab
    n1=en:antileukemic agent | n2=en:naptumomab | rel=r_associated | relid=0 | w=34
  92. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:odorant
    n1=en:antileukemic agent | n2=en:odorant | rel=r_associated | relid=0 | w=34
  93. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:olaparib
    n1=en:antileukemic agent | n2=en:olaparib | rel=r_associated | relid=0 | w=34
  94. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:ozone-based agent
    n1=en:antileukemic agent | n2=en:ozone-based agent | rel=r_associated | relid=0 | w=34
  95. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:panobinostat
    n1=en:antileukemic agent | n2=en:panobinostat | rel=r_associated | relid=0 | w=34
  96. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:pol i inhibitor cx5461
    n1=en:antileukemic agent | n2=en:pol i inhibitor cx5461 | rel=r_associated | relid=0 | w=34
  97. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:psychotropic agent
    n1=en:antileukemic agent | n2=en:psychotropic agent | rel=r_associated | relid=0 | w=34
  98. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:rapid-onset opioid
    n1=en:antileukemic agent | n2=en:rapid-onset opioid | rel=r_associated | relid=0 | w=34
  99. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:razoxane
    n1=en:antileukemic agent | n2=en:razoxane | rel=r_associated | relid=0 | w=34
  100. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:sns01-t nanoparticles
    n1=en:antileukemic agent | n2=en:sns01-t nanoparticles | rel=r_associated | relid=0 | w=34
  101. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:sparfosic acid
    n1=en:antileukemic agent | n2=en:sparfosic acid | rel=r_associated | relid=0 | w=34
  102. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:synthesis inhibitors, dna
    n1=en:antileukemic agent | n2=en:synthesis inhibitors, dna | rel=r_associated | relid=0 | w=34
  103. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:synthetic antiandrogen
    n1=en:antileukemic agent | n2=en:synthetic antiandrogen | rel=r_associated | relid=0 | w=34
  104. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:synthetic antiestrogen
    n1=en:antileukemic agent | n2=en:synthetic antiestrogen | rel=r_associated | relid=0 | w=34
  105. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:testolactone
    n1=en:antileukemic agent | n2=en:testolactone | rel=r_associated | relid=0 | w=34
  106. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:tilorone
    n1=en:antileukemic agent | n2=en:tilorone | rel=r_associated | relid=0 | w=34
  107. en:antileukemic agent -- r_associated #0: 34 / 0.791 -> en:urokinase-derived peptide a6
    n1=en:antileukemic agent | n2=en:urokinase-derived peptide a6 | rel=r_associated | relid=0 | w=34
  108. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:ad5-cmv-nis
    n1=en:antileukemic agent | n2=en:ad5-cmv-nis | rel=r_associated | relid=0 | w=32
  109. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:adjunct agent
    n1=en:antileukemic agent | n2=en:adjunct agent | rel=r_associated | relid=0 | w=32
  110. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:anticarcinogenic agents
    n1=en:antileukemic agent | n2=en:anticarcinogenic agents | rel=r_associated | relid=0 | w=32
  111. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:antimitotic agent
    n1=en:antileukemic agent | n2=en:antimitotic agent | rel=r_associated | relid=0 | w=32
  112. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:antineoplastic adjuvants
    n1=en:antileukemic agent | n2=en:antineoplastic adjuvants | rel=r_associated | relid=0 | w=32
  113. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:antineoplastic radiopharmaceuticals
    n1=en:antileukemic agent | n2=en:antineoplastic radiopharmaceuticals | rel=r_associated | relid=0 | w=32
  114. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:artemether sublingual spray
    n1=en:antileukemic agent | n2=en:artemether sublingual spray | rel=r_associated | relid=0 | w=32
  115. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:beta-elemene
    n1=en:antileukemic agent | n2=en:beta-elemene | rel=r_associated | relid=0 | w=32
  116. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:beta-lapachone prodrug arq 761
    n1=en:antileukemic agent | n2=en:beta-lapachone prodrug arq 761 | rel=r_associated | relid=0 | w=32
  117. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:bh3 mimetic abt-737
    n1=en:antileukemic agent | n2=en:bh3 mimetic abt-737 | rel=r_associated | relid=0 | w=32
  118. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:boron delivery agent
    n1=en:antileukemic agent | n2=en:boron delivery agent | rel=r_associated | relid=0 | w=32
  119. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:budotitane
    n1=en:antileukemic agent | n2=en:budotitane | rel=r_associated | relid=0 | w=32
  120. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:carboxyamidotriazole orotate
    n1=en:antileukemic agent | n2=en:carboxyamidotriazole orotate | rel=r_associated | relid=0 | w=32
  121. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:cd5789 cream
    n1=en:antileukemic agent | n2=en:cd5789 cream | rel=r_associated | relid=0 | w=32
  122. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:chlorambucil
    n1=en:antileukemic agent | n2=en:chlorambucil | rel=r_associated | relid=0 | w=32
  123. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:cyproterone
    n1=en:antileukemic agent | n2=en:cyproterone | rel=r_associated | relid=0 | w=32
  124. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:e2f1 pathway activator arq 171
    n1=en:antileukemic agent | n2=en:e2f1 pathway activator arq 171 | rel=r_associated | relid=0 | w=32
  125. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:enzyme inhibitor
    n1=en:antileukemic agent | n2=en:enzyme inhibitor | rel=r_associated | relid=0 | w=32
  126. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:fact complex-targeting curaxin cbl0137
    n1=en:antileukemic agent | n2=en:fact complex-targeting curaxin cbl0137 | rel=r_associated | relid=0 | w=32
  127. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:floxuridine
    n1=en:antileukemic agent | n2=en:floxuridine | rel=r_associated | relid=0 | w=32
  128. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:gemtuzumab ozogamicin
    n1=en:antileukemic agent | n2=en:gemtuzumab ozogamicin | rel=r_associated | relid=0 | w=32
  129. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:hdm2 inhibitor hdm201
    n1=en:antileukemic agent | n2=en:hdm2 inhibitor hdm201 | rel=r_associated | relid=0 | w=32
  130. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:ibritumomab
    n1=en:antileukemic agent | n2=en:ibritumomab | rel=r_associated | relid=0 | w=32
  131. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:ibritumomab tiuxetan
    n1=en:antileukemic agent | n2=en:ibritumomab tiuxetan | rel=r_associated | relid=0 | w=32
  132. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:imiquimod
    n1=en:antileukemic agent | n2=en:imiquimod | rel=r_associated | relid=0 | w=32
  133. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:jin fu kang
    n1=en:antileukemic agent | n2=en:jin fu kang | rel=r_associated | relid=0 | w=32
  134. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:liposome-encapsulated mir-34 mimic mrx34
    n1=en:antileukemic agent | n2=en:liposome-encapsulated mir-34 mimic mrx34 | rel=r_associated | relid=0 | w=32
  135. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:maltose tetrapalmitate
    n1=en:antileukemic agent | n2=en:maltose tetrapalmitate | rel=r_associated | relid=0 | w=32
  136. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:megestrol
    n1=en:antileukemic agent | n2=en:megestrol | rel=r_associated | relid=0 | w=32
  137. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads
    n1=en:antileukemic agent | n2=en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads | rel=r_associated | relid=0 | w=32
  138. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:nutraceutical
    n1=en:antileukemic agent | n2=en:nutraceutical | rel=r_associated | relid=0 | w=32
  139. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:orphan drug
    n1=en:antileukemic agent | n2=en:orphan drug | rel=r_associated | relid=0 | w=32
  140. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:oxphos inhibitor vlx600
    n1=en:antileukemic agent | n2=en:oxphos inhibitor vlx600 | rel=r_associated | relid=0 | w=32
  141. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:p-cadherin inhibitor pca062
    n1=en:antileukemic agent | n2=en:p-cadherin inhibitor pca062 | rel=r_associated | relid=0 | w=32
  142. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:p53/hdm2 interaction inhibitor cgm097
    n1=en:antileukemic agent | n2=en:p53/hdm2 interaction inhibitor cgm097 | rel=r_associated | relid=0 | w=32
  143. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:pegylated human recombinant arginase 1 aeb1102
    n1=en:antileukemic agent | n2=en:pegylated human recombinant arginase 1 aeb1102 | rel=r_associated | relid=0 | w=32
  144. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:plevitrexed
    n1=en:antileukemic agent | n2=en:plevitrexed | rel=r_associated | relid=0 | w=32
  145. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:pomalidomide
    n1=en:antileukemic agent | n2=en:pomalidomide | rel=r_associated | relid=0 | w=32
  146. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:radiosensitizing agent
    n1=en:antileukemic agent | n2=en:radiosensitizing agent | rel=r_associated | relid=0 | w=32
  147. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:ruthenium-based transferrin targeting agent nkp-1339
    n1=en:antileukemic agent | n2=en:ruthenium-based transferrin targeting agent nkp-1339 | rel=r_associated | relid=0 | w=32
  148. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:sodium dichloroacetate
    n1=en:antileukemic agent | n2=en:sodium dichloroacetate | rel=r_associated | relid=0 | w=32
  149. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:teglarinad
    n1=en:antileukemic agent | n2=en:teglarinad | rel=r_associated | relid=0 | w=32
  150. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:thyrotropin alfa
    n1=en:antileukemic agent | n2=en:thyrotropin alfa | rel=r_associated | relid=0 | w=32
  151. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:vinblastine
    n1=en:antileukemic agent | n2=en:vinblastine | rel=r_associated | relid=0 | w=32
  152. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:xiap/ciap1 antagonist astx660
    n1=en:antileukemic agent | n2=en:xiap/ciap1 antagonist astx660 | rel=r_associated | relid=0 | w=32
  153. en:antileukemic agent -- r_associated #0: 32 / 0.744 -> en:yangzheng xiaoji extract
    n1=en:antileukemic agent | n2=en:yangzheng xiaoji extract | rel=r_associated | relid=0 | w=32
  154. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:alpha-tocopheryloxyacetic acid
    n1=en:antileukemic agent | n2=en:alpha-tocopheryloxyacetic acid | rel=r_associated | relid=0 | w=31
  155. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:alvocidib hydrochloride
    n1=en:antileukemic agent | n2=en:alvocidib hydrochloride | rel=r_associated | relid=0 | w=31
  156. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:aminolevulinic acid
    n1=en:antileukemic agent | n2=en:aminolevulinic acid | rel=r_associated | relid=0 | w=31
  157. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:anti-androgen
    n1=en:antileukemic agent | n2=en:anti-androgen | rel=r_associated | relid=0 | w=31
  158. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:antineoplastic alkylating agent
    n1=en:antileukemic agent | n2=en:antineoplastic alkylating agent | rel=r_associated | relid=0 | w=31
  159. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:antineoplastic metal complex agent
    n1=en:antileukemic agent | n2=en:antineoplastic metal complex agent | rel=r_associated | relid=0 | w=31
  160. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:apoptosis inducer bzl101
    n1=en:antileukemic agent | n2=en:apoptosis inducer bzl101 | rel=r_associated | relid=0 | w=31
  161. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:arsenic
    n1=en:antileukemic agent | n2=en:arsenic | rel=r_associated | relid=0 | w=31
  162. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:azacitidine
    n1=en:antileukemic agent | n2=en:azacitidine | rel=r_associated | relid=0 | w=31
  163. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:azurin:50-77 cell penetrating peptide p28
    n1=en:antileukemic agent | n2=en:azurin:50-77 cell penetrating peptide p28 | rel=r_associated | relid=0 | w=31
  164. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:bcl-2 inhibitor bcl201
    n1=en:antileukemic agent | n2=en:bcl-2 inhibitor bcl201 | rel=r_associated | relid=0 | w=31
  165. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:bryostatin 1
    n1=en:antileukemic agent | n2=en:bryostatin 1 | rel=r_associated | relid=0 | w=31
  166. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:bulk-forming agent
    n1=en:antileukemic agent | n2=en:bulk-forming agent | rel=r_associated | relid=0 | w=31
  167. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:caricotamide/tretazicar
    n1=en:antileukemic agent | n2=en:caricotamide/tretazicar | rel=r_associated | relid=0 | w=31
  168. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:compound kushen injection
    n1=en:antileukemic agent | n2=en:compound kushen injection | rel=r_associated | relid=0 | w=31
  169. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:cxcr4 peptide antagonist ly2510924
    n1=en:antileukemic agent | n2=en:cxcr4 peptide antagonist ly2510924 | rel=r_associated | relid=0 | w=31
  170. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:daratumumab
    n1=en:antileukemic agent | n2=en:daratumumab | rel=r_associated | relid=0 | w=31
  171. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:diethylstilbestrol
    n1=en:antileukemic agent | n2=en:diethylstilbestrol | rel=r_associated | relid=0 | w=31
  172. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:dta-h19 plasmid
    n1=en:antileukemic agent | n2=en:dta-h19 plasmid | rel=r_associated | relid=0 | w=31
  173. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:epha2-targeting dopc-encapsulated sirna
    n1=en:antileukemic agent | n2=en:epha2-targeting dopc-encapsulated sirna | rel=r_associated | relid=0 | w=31
  174. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:fgf receptor antagonist hgs1036
    n1=en:antileukemic agent | n2=en:fgf receptor antagonist hgs1036 | rel=r_associated | relid=0 | w=31
  175. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:gallium nitrate
    n1=en:antileukemic agent | n2=en:gallium nitrate | rel=r_associated | relid=0 | w=31
  176. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:generic drug
    n1=en:antileukemic agent | n2=en:generic drug | rel=r_associated | relid=0 | w=31
  177. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:glucocorticoid receptor antagonist cort125134
    n1=en:antileukemic agent | n2=en:glucocorticoid receptor antagonist cort125134 | rel=r_associated | relid=0 | w=31
  178. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:glutathione disulfide nov-002
    n1=en:antileukemic agent | n2=en:glutathione disulfide nov-002 | rel=r_associated | relid=0 | w=31
  179. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:harringtonines
    n1=en:antileukemic agent | n2=en:harringtonines | rel=r_associated | relid=0 | w=31
  180. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:iap inhibitor at-406
    n1=en:antileukemic agent | n2=en:iap inhibitor at-406 | rel=r_associated | relid=0 | w=31
  181. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:immunomodulating agent
    n1=en:antileukemic agent | n2=en:immunomodulating agent | rel=r_associated | relid=0 | w=31
  182. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:interleukin inhibitor
    n1=en:antileukemic agent | n2=en:interleukin inhibitor | rel=r_associated | relid=0 | w=31
  183. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:lipid encapsulated anti-plk1 sirna tkm-plk1
    n1=en:antileukemic agent | n2=en:lipid encapsulated anti-plk1 sirna tkm-plk1 | rel=r_associated | relid=0 | w=31
  184. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:lomustine
    n1=en:antileukemic agent | n2=en:lomustine | rel=r_associated | relid=0 | w=31
  185. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:mdm2 antagonist ro5045337
    n1=en:antileukemic agent | n2=en:mdm2 antagonist ro5045337 | rel=r_associated | relid=0 | w=31
  186. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:melphalan
    n1=en:antileukemic agent | n2=en:melphalan | rel=r_associated | relid=0 | w=31
  187. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:methoxyamine hydrochloride
    n1=en:antileukemic agent | n2=en:methoxyamine hydrochloride | rel=r_associated | relid=0 | w=31
  188. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:miltefosine
    n1=en:antileukemic agent | n2=en:miltefosine | rel=r_associated | relid=0 | w=31
  189. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:morinda citrifolia fruit extract
    n1=en:antileukemic agent | n2=en:morinda citrifolia fruit extract | rel=r_associated | relid=0 | w=31
  190. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:mutant p53 activator coti-2
    n1=en:antileukemic agent | n2=en:mutant p53 activator coti-2 | rel=r_associated | relid=0 | w=31
  191. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:myc-targeting sirna dcr-myc
    n1=en:antileukemic agent | n2=en:myc-targeting sirna dcr-myc | rel=r_associated | relid=0 | w=31
  192. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:obatoclax
    n1=en:antileukemic agent | n2=en:obatoclax | rel=r_associated | relid=0 | w=31
  193. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:opioid growth factor
    n1=en:antileukemic agent | n2=en:opioid growth factor | rel=r_associated | relid=0 | w=31
  194. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:oregovomab
    n1=en:antileukemic agent | n2=en:oregovomab | rel=r_associated | relid=0 | w=31
  195. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:pbn derivative okn-007
    n1=en:antileukemic agent | n2=en:pbn derivative okn-007 | rel=r_associated | relid=0 | w=31
  196. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:pharmaceutical product-related substance
    n1=en:antileukemic agent | n2=en:pharmaceutical product-related substance | rel=r_associated | relid=0 | w=31
  197. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:photosensitizing agent
    n1=en:antileukemic agent | n2=en:photosensitizing agent | rel=r_associated | relid=0 | w=31
  198. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:pr-104
    n1=en:antileukemic agent | n2=en:pr-104 | rel=r_associated | relid=0 | w=31
  199. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:procaspase activating compound-1 vo-100
    n1=en:antileukemic agent | n2=en:procaspase activating compound-1 vo-100 | rel=r_associated | relid=0 | w=31
  200. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:proteasome inhibitor
    n1=en:antileukemic agent | n2=en:proteasome inhibitor | rel=r_associated | relid=0 | w=31
  201. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:quinacrine hydrochloride
    n1=en:antileukemic agent | n2=en:quinacrine hydrochloride | rel=r_associated | relid=0 | w=31
  202. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:ribosome-inactivating protein cy503
    n1=en:antileukemic agent | n2=en:ribosome-inactivating protein cy503 | rel=r_associated | relid=0 | w=31
  203. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:stressor
    n1=en:antileukemic agent | n2=en:stressor | rel=r_associated | relid=0 | w=31
  204. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:talimogene laherparepvec
    n1=en:antileukemic agent | n2=en:talimogene laherparepvec | rel=r_associated | relid=0 | w=31
  205. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:trimetrexate
    n1=en:antileukemic agent | n2=en:trimetrexate | rel=r_associated | relid=0 | w=31
  206. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:tyroserleutide
    n1=en:antileukemic agent | n2=en:tyroserleutide | rel=r_associated | relid=0 | w=31
  207. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:vorinostat
    n1=en:antileukemic agent | n2=en:vorinostat | rel=r_associated | relid=0 | w=31
  208. en:antileukemic agent -- r_associated #0: 31 / 0.721 -> en:xpo1 inhibitor kpt-8602
    n1=en:antileukemic agent | n2=en:xpo1 inhibitor kpt-8602 | rel=r_associated | relid=0 | w=31
  209. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:adenosine a3 receptor agonist cf102
    n1=en:antileukemic agent | n2=en:adenosine a3 receptor agonist cf102 | rel=r_associated | relid=0 | w=30
  210. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:agglutinin
    n1=en:antileukemic agent | n2=en:agglutinin | rel=r_associated | relid=0 | w=30
  211. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:amphotericin product
    n1=en:antileukemic agent | n2=en:amphotericin product | rel=r_associated | relid=0 | w=30
  212. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:anti-transthyretin sirna aln-ttr02
    n1=en:antileukemic agent | n2=en:anti-transthyretin sirna aln-ttr02 | rel=r_associated | relid=0 | w=30
  213. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:antineoplastic alkaloid
    n1=en:antileukemic agent | n2=en:antineoplastic alkaloid | rel=r_associated | relid=0 | w=30
  214. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:asparaginase
    n1=en:antileukemic agent | n2=en:asparaginase | rel=r_associated | relid=0 | w=30
  215. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:brentuximab vedotin
    n1=en:antileukemic agent | n2=en:brentuximab vedotin | rel=r_associated | relid=0 | w=30
  216. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:camptothecin
    n1=en:antileukemic agent | n2=en:camptothecin | rel=r_associated | relid=0 | w=30
  217. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:cancell
    n1=en:antileukemic agent | n2=en:cancell | rel=r_associated | relid=0 | w=30
  218. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:cyclophosphamide
    n1=en:antileukemic agent | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=30
  219. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:darinaparsin
    n1=en:antileukemic agent | n2=en:darinaparsin | rel=r_associated | relid=0 | w=30
  220. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:elesclomol
    n1=en:antileukemic agent | n2=en:elesclomol | rel=r_associated | relid=0 | w=30
  221. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:elesclomol sodium
    n1=en:antileukemic agent | n2=en:elesclomol sodium | rel=r_associated | relid=0 | w=30
  222. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:ep4 receptor antagonist aat-007
    n1=en:antileukemic agent | n2=en:ep4 receptor antagonist aat-007 | rel=r_associated | relid=0 | w=30
  223. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:epothilone compound
    n1=en:antileukemic agent | n2=en:epothilone compound | rel=r_associated | relid=0 | w=30
  224. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:everolimus
    n1=en:antileukemic agent | n2=en:everolimus | rel=r_associated | relid=0 | w=30
  225. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:finasteride
    n1=en:antileukemic agent | n2=en:finasteride | rel=r_associated | relid=0 | w=30
  226. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:fludarabine
    n1=en:antileukemic agent | n2=en:fludarabine | rel=r_associated | relid=0 | w=30
  227. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:galectin inhibitor gr-md-02
    n1=en:antileukemic agent | n2=en:galectin inhibitor gr-md-02 | rel=r_associated | relid=0 | w=30
  228. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:hif-2alpha inhibitor pt2385
    n1=en:antileukemic agent | n2=en:hif-2alpha inhibitor pt2385 | rel=r_associated | relid=0 | w=30
  229. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:huachansu
    n1=en:antileukemic agent | n2=en:huachansu | rel=r_associated | relid=0 | w=30
  230. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:idelalisib
    n1=en:antileukemic agent | n2=en:idelalisib | rel=r_associated | relid=0 | w=30
  231. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:lactoferrin-derived lytic peptide ltx-315
    n1=en:antileukemic agent | n2=en:lactoferrin-derived lytic peptide ltx-315 | rel=r_associated | relid=0 | w=30
  232. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:lapachone
    n1=en:antileukemic agent | n2=en:lapachone | rel=r_associated | relid=0 | w=30
  233. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:nanocell-encapsulated mir-16-based microrna mimic
    n1=en:antileukemic agent | n2=en:nanocell-encapsulated mir-16-based microrna mimic | rel=r_associated | relid=0 | w=30
  234. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:pleiotropic pathway modifier cc-122 hydrochloride
    n1=en:antileukemic agent | n2=en:pleiotropic pathway modifier cc-122 hydrochloride | rel=r_associated | relid=0 | w=30
  235. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:sdf-1-targeted agent nox-a12
    n1=en:antileukemic agent | n2=en:sdf-1-targeted agent nox-a12 | rel=r_associated | relid=0 | w=30
  236. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:selinexor
    n1=en:antileukemic agent | n2=en:selinexor | rel=r_associated | relid=0 | w=30
  237. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:sig12d loder
    n1=en:antileukemic agent | n2=en:sig12d loder | rel=r_associated | relid=0 | w=30
  238. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:siltuximab
    n1=en:antileukemic agent | n2=en:siltuximab | rel=r_associated | relid=0 | w=30
  239. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:temozolomide
    n1=en:antileukemic agent | n2=en:temozolomide | rel=r_associated | relid=0 | w=30
  240. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:thiotepa
    n1=en:antileukemic agent | n2=en:thiotepa | rel=r_associated | relid=0 | w=30
  241. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:tolnidamine
    n1=en:antileukemic agent | n2=en:tolnidamine | rel=r_associated | relid=0 | w=30
  242. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:tositumomab
    n1=en:antileukemic agent | n2=en:tositumomab | rel=r_associated | relid=0 | w=30
  243. en:antileukemic agent -- r_associated #0: 30 / 0.698 -> en:vegf/hgf-targeting darpin mp0250
    n1=en:antileukemic agent | n2=en:vegf/hgf-targeting darpin mp0250 | rel=r_associated | relid=0 | w=30
  244. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:alkylating agent
    n1=en:antileukemic agent | n2=en:alkylating agent | rel=r_associated | relid=0 | w=29
  245. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:antimetastatic agent
    n1=en:antileukemic agent | n2=en:antimetastatic agent | rel=r_associated | relid=0 | w=29
  246. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:antineoplastic agent combination sm-88
    n1=en:antileukemic agent | n2=en:antineoplastic agent combination sm-88 | rel=r_associated | relid=0 | w=29
  247. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:antipneumocystis agent
    n1=en:antileukemic agent | n2=en:antipneumocystis agent | rel=r_associated | relid=0 | w=29
  248. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:blinatumomab
    n1=en:antileukemic agent | n2=en:blinatumomab | rel=r_associated | relid=0 | w=29
  249. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:carbohydrate processing inhibitor
    n1=en:antileukemic agent | n2=en:carbohydrate processing inhibitor | rel=r_associated | relid=0 | w=29
  250. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:cephalostatin
    n1=en:antileukemic agent | n2=en:cephalostatin | rel=r_associated | relid=0 | w=29
  251. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:chemotherapeutic topical agent
    n1=en:antileukemic agent | n2=en:chemotherapeutic topical agent | rel=r_associated | relid=0 | w=29
  252. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:cycle-phase nonspecific agent
    n1=en:antileukemic agent | n2=en:cycle-phase nonspecific agent | rel=r_associated | relid=0 | w=29
  253. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:cytokine agent
    n1=en:antileukemic agent | n2=en:cytokine agent | rel=r_associated | relid=0 | w=29
  254. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:cytotoxic agent
    n1=en:antileukemic agent | n2=en:cytotoxic agent | rel=r_associated | relid=0 | w=29
  255. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:dexanabinol
    n1=en:antileukemic agent | n2=en:dexanabinol | rel=r_associated | relid=0 | w=29
  256. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:diarylsulfonylurea compound
    n1=en:antileukemic agent | n2=en:diarylsulfonylurea compound | rel=r_associated | relid=0 | w=29
  257. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:dna binding agent
    n1=en:antileukemic agent | n2=en:dna binding agent | rel=r_associated | relid=0 | w=29
  258. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:dna-rna transcription regulator
    n1=en:antileukemic agent | n2=en:dna-rna transcription regulator | rel=r_associated | relid=0 | w=29
  259. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:epidermal growth factor receptor tyrosine kinase inhibitor
    n1=en:antileukemic agent | n2=en:epidermal growth factor receptor tyrosine kinase inhibitor | rel=r_associated | relid=0 | w=29
  260. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:fenretinide
    n1=en:antileukemic agent | n2=en:fenretinide | rel=r_associated | relid=0 | w=29
  261. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:huaier extract granule
    n1=en:antileukemic agent | n2=en:huaier extract granule | rel=r_associated | relid=0 | w=29
  262. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:ingenol mebutate
    n1=en:antileukemic agent | n2=en:ingenol mebutate | rel=r_associated | relid=0 | w=29
  263. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:irinotecan
    n1=en:antileukemic agent | n2=en:irinotecan | rel=r_associated | relid=0 | w=29
  264. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:leuprolide
    n1=en:antileukemic agent | n2=en:leuprolide | rel=r_associated | relid=0 | w=29
  265. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:mdm2/mdmx inhibitor alrn-6924
    n1=en:antileukemic agent | n2=en:mdm2/mdmx inhibitor alrn-6924 | rel=r_associated | relid=0 | w=29
  266. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:metaiodobenzylguanidine[131i]
    n1=en:antileukemic agent | n2=en:metaiodobenzylguanidine[131i] | rel=r_associated | relid=0 | w=29
  267. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:molecular target inhibitors
    n1=en:antileukemic agent | n2=en:molecular target inhibitors | rel=r_associated | relid=0 | w=29
  268. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:monocarboxylate transporter 1 inhibitor azd3965
    n1=en:antileukemic agent | n2=en:monocarboxylate transporter 1 inhibitor azd3965 | rel=r_associated | relid=0 | w=29
  269. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:monoclonal antibodies, antineoplastic
    n1=en:antileukemic agent | n2=en:monoclonal antibodies, antineoplastic | rel=r_associated | relid=0 | w=29
  270. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:myeloablative agonist
    n1=en:antileukemic agent | n2=en:myeloablative agonist | rel=r_associated | relid=0 | w=29
  271. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:napabucasin
    n1=en:antileukemic agent | n2=en:napabucasin | rel=r_associated | relid=0 | w=29
  272. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:non-cytotoxic agent
    n1=en:antileukemic agent | n2=en:non-cytotoxic agent | rel=r_associated | relid=0 | w=29
  273. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:oblimersen
    n1=en:antileukemic agent | n2=en:oblimersen | rel=r_associated | relid=0 | w=29
  274. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:piroxicam
    n1=en:antileukemic agent | n2=en:piroxicam | rel=r_associated | relid=0 | w=29
  275. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:poly (adp-ribose) polymerase inhibitor
    n1=en:antileukemic agent | n2=en:poly (adp-ribose) polymerase inhibitor | rel=r_associated | relid=0 | w=29
  276. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:samarium sm-153 lexidronam pentasodium
    n1=en:antileukemic agent | n2=en:samarium sm-153 lexidronam pentasodium | rel=r_associated | relid=0 | w=29
  277. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:selective estrogen receptor modulator
    n1=en:antileukemic agent | n2=en:selective estrogen receptor modulator | rel=r_associated | relid=0 | w=29
  278. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:sodium borocaptate
    n1=en:antileukemic agent | n2=en:sodium borocaptate | rel=r_associated | relid=0 | w=29
  279. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:spermicide
    n1=en:antileukemic agent | n2=en:spermicide | rel=r_associated | relid=0 | w=29
  280. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:tazemetostat
    n1=en:antileukemic agent | n2=en:tazemetostat | rel=r_associated | relid=0 | w=29
  281. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:thioureidobutyronitrile
    n1=en:antileukemic agent | n2=en:thioureidobutyronitrile | rel=r_associated | relid=0 | w=29
  282. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:tirapazamine
    n1=en:antileukemic agent | n2=en:tirapazamine | rel=r_associated | relid=0 | w=29
  283. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:topsalysin
    n1=en:antileukemic agent | n2=en:topsalysin | rel=r_associated | relid=0 | w=29
  284. en:antileukemic agent -- r_associated #0: 29 / 0.674 -> en:vismodegib
    n1=en:antileukemic agent | n2=en:vismodegib | rel=r_associated | relid=0 | w=29
  285. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:2-hydroxyoleic acid
    n1=en:antileukemic agent | n2=en:2-hydroxyoleic acid | rel=r_associated | relid=0 | w=28
  286. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:additive
    n1=en:antileukemic agent | n2=en:additive | rel=r_associated | relid=0 | w=28
  287. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:aminoglutethimide
    n1=en:antileukemic agent | n2=en:aminoglutethimide | rel=r_associated | relid=0 | w=28
  288. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:anti-pkn3 sirna atu027
    n1=en:antileukemic agent | n2=en:anti-pkn3 sirna atu027 | rel=r_associated | relid=0 | w=28
  289. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:antineoplastic agent
    n1=en:antileukemic agent | n2=en:antineoplastic agent | rel=r_associated | relid=0 | w=28
  290. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:antineoplastic hormones
    n1=en:antileukemic agent | n2=en:antineoplastic hormones | rel=r_associated | relid=0 | w=28
  291. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:azapicyl
    n1=en:antileukemic agent | n2=en:azapicyl | rel=r_associated | relid=0 | w=28
  292. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex
    n1=en:antileukemic agent | n2=en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex | rel=r_associated | relid=0 | w=28
  293. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:cisplatin
    n1=en:antileukemic agent | n2=en:cisplatin | rel=r_associated | relid=0 | w=28
  294. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:ck2-targeting synthetic peptide cigb-300
    n1=en:antileukemic agent | n2=en:ck2-targeting synthetic peptide cigb-300 | rel=r_associated | relid=0 | w=28
  295. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:dacarbazine
    n1=en:antileukemic agent | n2=en:dacarbazine | rel=r_associated | relid=0 | w=28
  296. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:digestant
    n1=en:antileukemic agent | n2=en:digestant | rel=r_associated | relid=0 | w=28
  297. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:erythrocyte-encapsulated l-asparaginase suspension
    n1=en:antileukemic agent | n2=en:erythrocyte-encapsulated l-asparaginase suspension | rel=r_associated | relid=0 | w=28
  298. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:etidronate-cytarabine conjugate mbc-11
    n1=en:antileukemic agent | n2=en:etidronate-cytarabine conjugate mbc-11 | rel=r_associated | relid=0 | w=28
  299. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:etoposide
    n1=en:antileukemic agent | n2=en:etoposide | rel=r_associated | relid=0 | w=28
  300. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:fazarabine
    n1=en:antileukemic agent | n2=en:fazarabine | rel=r_associated | relid=0 | w=28
  301. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225
    n1=en:antileukemic agent | n2=en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 | rel=r_associated | relid=0 | w=28
  302. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:fosquidone
    n1=en:antileukemic agent | n2=en:fosquidone | rel=r_associated | relid=0 | w=28
  303. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:gemcitabine
    n1=en:antileukemic agent | n2=en:gemcitabine | rel=r_associated | relid=0 | w=28
  304. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:haemato fu
    n1=en:antileukemic agent | n2=en:haemato fu | rel=r_associated | relid=0 | w=28
  305. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:heat shock protein inhibitor
    n1=en:antileukemic agent | n2=en:heat shock protein inhibitor | rel=r_associated | relid=0 | w=28
  306. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:ifosfamide
    n1=en:antileukemic agent | n2=en:ifosfamide | rel=r_associated | relid=0 | w=28
  307. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:illicit substance
    n1=en:antileukemic agent | n2=en:illicit substance | rel=r_associated | relid=0 | w=28
  308. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:investigational new drug
    n1=en:antileukemic agent | n2=en:investigational new drug | rel=r_associated | relid=0 | w=28
  309. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:mipsagargin
    n1=en:antileukemic agent | n2=en:mipsagargin | rel=r_associated | relid=0 | w=28
  310. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:nanoparticle-targeted drug
    n1=en:antileukemic agent | n2=en:nanoparticle-targeted drug | rel=r_associated | relid=0 | w=28
  311. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:oleandrin
    n1=en:antileukemic agent | n2=en:oleandrin | rel=r_associated | relid=0 | w=28
  312. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:p-cadherin antagonist pf-03732010
    n1=en:antileukemic agent | n2=en:p-cadherin antagonist pf-03732010 | rel=r_associated | relid=0 | w=28
  313. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:p53-hdm2 interaction inhibitor mi-773
    n1=en:antileukemic agent | n2=en:p53-hdm2 interaction inhibitor mi-773 | rel=r_associated | relid=0 | w=28
  314. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:pertuzumab
    n1=en:antileukemic agent | n2=en:pertuzumab | rel=r_associated | relid=0 | w=28
  315. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:pharmaceutical excipient
    n1=en:antileukemic agent | n2=en:pharmaceutical excipient | rel=r_associated | relid=0 | w=28
  316. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:prohibitin-targeting peptide 1
    n1=en:antileukemic agent | n2=en:prohibitin-targeting peptide 1 | rel=r_associated | relid=0 | w=28
  317. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:pyridyl cyanoguanidine chs 828
    n1=en:antileukemic agent | n2=en:pyridyl cyanoguanidine chs 828 | rel=r_associated | relid=0 | w=28
  318. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:quarfloxin
    n1=en:antileukemic agent | n2=en:quarfloxin | rel=r_associated | relid=0 | w=28
  319. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:ramucirumab
    n1=en:antileukemic agent | n2=en:ramucirumab | rel=r_associated | relid=0 | w=28
  320. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:realgar-indigo naturalis formulation
    n1=en:antileukemic agent | n2=en:realgar-indigo naturalis formulation | rel=r_associated | relid=0 | w=28
  321. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:ruxolitinib
    n1=en:antileukemic agent | n2=en:ruxolitinib | rel=r_associated | relid=0 | w=28
  322. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:simtrazene
    n1=en:antileukemic agent | n2=en:simtrazene | rel=r_associated | relid=0 | w=28
  323. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:temsirolimus
    n1=en:antileukemic agent | n2=en:temsirolimus | rel=r_associated | relid=0 | w=28
  324. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:topoisomerase inhibitor
    n1=en:antileukemic agent | n2=en:topoisomerase inhibitor | rel=r_associated | relid=0 | w=28
  325. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:xanthohumol
    n1=en:antileukemic agent | n2=en:xanthohumol | rel=r_associated | relid=0 | w=28
  326. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:xpo1 inhibitor sl-801
    n1=en:antileukemic agent | n2=en:xpo1 inhibitor sl-801 | rel=r_associated | relid=0 | w=28
  327. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:z-360
    n1=en:antileukemic agent | n2=en:z-360 | rel=r_associated | relid=0 | w=28
  328. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:zanolimumab
    n1=en:antileukemic agent | n2=en:zanolimumab | rel=r_associated | relid=0 | w=28
  329. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> en:zinc finger nuclease zfn-758
    n1=en:antileukemic agent | n2=en:zinc finger nuclease zfn-758 | rel=r_associated | relid=0 | w=28
  330. en:antileukemic agent -- r_associated #0: 28 / 0.651 -> fluorouracile
    n1=en:antileukemic agent | n2=fluorouracile | rel=r_associated | relid=0 | w=28
  331. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:alloxan
    n1=en:antileukemic agent | n2=en:alloxan | rel=r_associated | relid=0 | w=27
  332. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:alpha-gal glycosphingolipids
    n1=en:antileukemic agent | n2=en:alpha-gal glycosphingolipids | rel=r_associated | relid=0 | w=27
  333. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:antimetabolite
    n1=en:antileukemic agent | n2=en:antimetabolite | rel=r_associated | relid=0 | w=27
  334. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:antineoplastic anthraquinone
    n1=en:antileukemic agent | n2=en:antineoplastic anthraquinone | rel=r_associated | relid=0 | w=27
  335. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:antineoplastics, other
    n1=en:antileukemic agent | n2=en:antineoplastics, other | rel=r_associated | relid=0 | w=27
  336. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:apoptosis inducer gcs-100
    n1=en:antileukemic agent | n2=en:apoptosis inducer gcs-100 | rel=r_associated | relid=0 | w=27
  337. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:asp4132
    n1=en:antileukemic agent | n2=en:asp4132 | rel=r_associated | relid=0 | w=27
  338. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:bc-819 plasmid/polyethylenimine complex
    n1=en:antileukemic agent | n2=en:bc-819 plasmid/polyethylenimine complex | rel=r_associated | relid=0 | w=27
  339. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:benaxibine
    n1=en:antileukemic agent | n2=en:benaxibine | rel=r_associated | relid=0 | w=27
  340. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:braf inhibitor
    n1=en:antileukemic agent | n2=en:braf inhibitor | rel=r_associated | relid=0 | w=27
  341. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:bromacrylide
    n1=en:antileukemic agent | n2=en:bromacrylide | rel=r_associated | relid=0 | w=27
  342. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:busulfan
    n1=en:antileukemic agent | n2=en:busulfan | rel=r_associated | relid=0 | w=27
  343. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:calculus bovis/moschus/olibanum/myrrha capsule
    n1=en:antileukemic agent | n2=en:calculus bovis/moschus/olibanum/myrrha capsule | rel=r_associated | relid=0 | w=27
  344. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:cell differentiating agent
    n1=en:antileukemic agent | n2=en:cell differentiating agent | rel=r_associated | relid=0 | w=27
  345. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:cycle-phase specific agent
    n1=en:antileukemic agent | n2=en:cycle-phase specific agent | rel=r_associated | relid=0 | w=27
  346. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:dopamine-somatostatin chimeric molecule bim-23a760
    n1=en:antileukemic agent | n2=en:dopamine-somatostatin chimeric molecule bim-23a760 | rel=r_associated | relid=0 | w=27
  347. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:e-selectin antagonist gmi-1271
    n1=en:antileukemic agent | n2=en:e-selectin antagonist gmi-1271 | rel=r_associated | relid=0 | w=27
  348. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:embolic agent
    n1=en:antileukemic agent | n2=en:embolic agent | rel=r_associated | relid=0 | w=27
  349. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:enteric-coated trpm8 agonist d-3263 hydrochloride
    n1=en:antileukemic agent | n2=en:enteric-coated trpm8 agonist d-3263 hydrochloride | rel=r_associated | relid=0 | w=27
  350. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:ets-family transcription factor inhibitor tk216
    n1=en:antileukemic agent | n2=en:ets-family transcription factor inhibitor tk216 | rel=r_associated | relid=0 | w=27
  351. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:flutamide
    n1=en:antileukemic agent | n2=en:flutamide | rel=r_associated | relid=0 | w=27
  352. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:gamboge resin extract tsb-9-w1
    n1=en:antileukemic agent | n2=en:gamboge resin extract tsb-9-w1 | rel=r_associated | relid=0 | w=27
  353. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:hif-1alpha inhibitor px-478
    n1=en:antileukemic agent | n2=en:hif-1alpha inhibitor px-478 | rel=r_associated | relid=0 | w=27
  354. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:hydroxyurea
    n1=en:antileukemic agent | n2=en:hydroxyurea | rel=r_associated | relid=0 | w=27
  355. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:iap inhibitor hgs1029
    n1=en:antileukemic agent | n2=en:iap inhibitor hgs1029 | rel=r_associated | relid=0 | w=27
  356. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:ipilimumab
    n1=en:antileukemic agent | n2=en:ipilimumab | rel=r_associated | relid=0 | w=27
  357. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:lysine-specific demethylase 1 inhibitor incb059872
    n1=en:antileukemic agent | n2=en:lysine-specific demethylase 1 inhibitor incb059872 | rel=r_associated | relid=0 | w=27
  358. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:mdm2 inhibitor amg-232
    n1=en:antileukemic agent | n2=en:mdm2 inhibitor amg-232 | rel=r_associated | relid=0 | w=27
  359. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:methotrexate
    n1=en:antileukemic agent | n2=en:methotrexate | rel=r_associated | relid=0 | w=27
  360. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:mitoxantrone
    n1=en:antileukemic agent | n2=en:mitoxantrone | rel=r_associated | relid=0 | w=27
  361. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:mycobacterial cell wall-dna complex
    n1=en:antileukemic agent | n2=en:mycobacterial cell wall-dna complex | rel=r_associated | relid=0 | w=27
  362. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:obatoclax mesylate
    n1=en:antileukemic agent | n2=en:obatoclax mesylate | rel=r_associated | relid=0 | w=27
  363. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:p-cadherin-targeting agent pf-06671008
    n1=en:antileukemic agent | n2=en:p-cadherin-targeting agent pf-06671008 | rel=r_associated | relid=0 | w=27
  364. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:penberol
    n1=en:antileukemic agent | n2=en:penberol | rel=r_associated | relid=0 | w=27
  365. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:personal care product
    n1=en:antileukemic agent | n2=en:personal care product | rel=r_associated | relid=0 | w=27
  366. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:polyamine analogue
    n1=en:antileukemic agent | n2=en:polyamine analogue | rel=r_associated | relid=0 | w=27
  367. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:pre-1938 product
    n1=en:antileukemic agent | n2=en:pre-1938 product | rel=r_associated | relid=0 | w=27
  368. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:protocol agent
    n1=en:antileukemic agent | n2=en:protocol agent | rel=r_associated | relid=0 | w=27
  369. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:recreational drug
    n1=en:antileukemic agent | n2=en:recreational drug | rel=r_associated | relid=0 | w=27
  370. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:smac mimetic lcl161
    n1=en:antileukemic agent | n2=en:smac mimetic lcl161 | rel=r_associated | relid=0 | w=27
  371. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:sr-t100 gel
    n1=en:antileukemic agent | n2=en:sr-t100 gel | rel=r_associated | relid=0 | w=27
  372. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:taurultam
    n1=en:antileukemic agent | n2=en:taurultam | rel=r_associated | relid=0 | w=27
  373. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:teglarinad chloride
    n1=en:antileukemic agent | n2=en:teglarinad chloride | rel=r_associated | relid=0 | w=27
  374. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:venetoclax
    n1=en:antileukemic agent | n2=en:venetoclax | rel=r_associated | relid=0 | w=27
  375. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:verteporfin
    n1=en:antileukemic agent | n2=en:verteporfin | rel=r_associated | relid=0 | w=27
  376. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:vinca alkaloid compound
    n1=en:antileukemic agent | n2=en:vinca alkaloid compound | rel=r_associated | relid=0 | w=27
  377. en:antileukemic agent -- r_associated #0: 27 / 0.628 -> en:vincristine
    n1=en:antileukemic agent | n2=en:vincristine | rel=r_associated | relid=0 | w=27
  378. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:amidino tic
    n1=en:antileukemic agent | n2=en:amidino tic | rel=r_associated | relid=0 | w=26
  379. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:antineoplastic agents, hormonal
    n1=en:antileukemic agent | n2=en:antineoplastic agents, hormonal | rel=r_associated | relid=0 | w=26
  380. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:apoptosis inducer mpc-2130
    n1=en:antileukemic agent | n2=en:apoptosis inducer mpc-2130 | rel=r_associated | relid=0 | w=26
  381. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:bromodomain inhibitor abbv-075
    n1=en:antileukemic agent | n2=en:bromodomain inhibitor abbv-075 | rel=r_associated | relid=0 | w=26
  382. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:carmustine
    n1=en:antileukemic agent | n2=en:carmustine | rel=r_associated | relid=0 | w=26
  383. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:catalyst
    n1=en:antileukemic agent | n2=en:catalyst | rel=r_associated | relid=0 | w=26
  384. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:catumaxomab
    n1=en:antileukemic agent | n2=en:catumaxomab | rel=r_associated | relid=0 | w=26
  385. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:cedefingol
    n1=en:antileukemic agent | n2=en:cedefingol | rel=r_associated | relid=0 | w=26
  386. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:cytostatic agents
    n1=en:antileukemic agent | n2=en:cytostatic agents | rel=r_associated | relid=0 | w=26
  387. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:elotuzumab
    n1=en:antileukemic agent | n2=en:elotuzumab | rel=r_associated | relid=0 | w=26
  388. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:erastin analogue prlx 93936
    n1=en:antileukemic agent | n2=en:erastin analogue prlx 93936 | rel=r_associated | relid=0 | w=26
  389. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:fluorouracil
    n1=en:antileukemic agent | n2=en:fluorouracil | rel=r_associated | relid=0 | w=26
  390. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:hafnium oxide-containing nanoparticles nbtxr3
    n1=en:antileukemic agent | n2=en:hafnium oxide-containing nanoparticles nbtxr3 | rel=r_associated | relid=0 | w=26
  391. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:hdm2 inhibitor mk-8242
    n1=en:antileukemic agent | n2=en:hdm2 inhibitor mk-8242 | rel=r_associated | relid=0 | w=26
  392. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:heparan sulfate glycosaminoglycan mimetic m402
    n1=en:antileukemic agent | n2=en:heparan sulfate glycosaminoglycan mimetic m402 | rel=r_associated | relid=0 | w=26
  393. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:idasanutlin
    n1=en:antileukemic agent | n2=en:idasanutlin | rel=r_associated | relid=0 | w=26
  394. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:ingenol mebutate gel
    n1=en:antileukemic agent | n2=en:ingenol mebutate gel | rel=r_associated | relid=0 | w=26
  395. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:lsd1 inhibitor gsk2879552
    n1=en:antileukemic agent | n2=en:lsd1 inhibitor gsk2879552 | rel=r_associated | relid=0 | w=26
  396. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:mdm2 antagonist ro6839921
    n1=en:antileukemic agent | n2=en:mdm2 antagonist ro6839921 | rel=r_associated | relid=0 | w=26
  397. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:mercuric cyanide
    n1=en:antileukemic agent | n2=en:mercuric cyanide | rel=r_associated | relid=0 | w=26
  398. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:nucleolin antagonist ipp-204106n
    n1=en:antileukemic agent | n2=en:nucleolin antagonist ipp-204106n | rel=r_associated | relid=0 | w=26
  399. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:nutlin-3a
    n1=en:antileukemic agent | n2=en:nutlin-3a | rel=r_associated | relid=0 | w=26
  400. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:over the counter product
    n1=en:antileukemic agent | n2=en:over the counter product | rel=r_associated | relid=0 | w=26
  401. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:pbi-shrna stmn1 lipoplex
    n1=en:antileukemic agent | n2=en:pbi-shrna stmn1 lipoplex | rel=r_associated | relid=0 | w=26
  402. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:pegylated recombinant l-asparaginase erwinia chrysanthemi
    n1=en:antileukemic agent | n2=en:pegylated recombinant l-asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=26
  403. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:polyamine synthesis inhibitor
    n1=en:antileukemic agent | n2=en:polyamine synthesis inhibitor | rel=r_associated | relid=0 | w=26
  404. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:pre-medication
    n1=en:antileukemic agent | n2=en:pre-medication | rel=r_associated | relid=0 | w=26
  405. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:prima-1 analog apr-246
    n1=en:antileukemic agent | n2=en:prima-1 analog apr-246 | rel=r_associated | relid=0 | w=26
  406. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:pv-10
    n1=en:antileukemic agent | n2=en:pv-10 | rel=r_associated | relid=0 | w=26
  407. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:retinoic acid agent
    n1=en:antileukemic agent | n2=en:retinoic acid agent | rel=r_associated | relid=0 | w=26
  408. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:rituximab
    n1=en:antileukemic agent | n2=en:rituximab | rel=r_associated | relid=0 | w=26
  409. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:signal transduction inhibitor
    n1=en:antileukemic agent | n2=en:signal transduction inhibitor | rel=r_associated | relid=0 | w=26
  410. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:splicing inhibitor h3b-8800
    n1=en:antileukemic agent | n2=en:splicing inhibitor h3b-8800 | rel=r_associated | relid=0 | w=26
  411. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:terfluranol
    n1=en:antileukemic agent | n2=en:terfluranol | rel=r_associated | relid=0 | w=26
  412. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:tigapotide
    n1=en:antileukemic agent | n2=en:tigapotide | rel=r_associated | relid=0 | w=26
  413. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:tretazicar
    n1=en:antileukemic agent | n2=en:tretazicar | rel=r_associated | relid=0 | w=26
  414. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:triptorelin
    n1=en:antileukemic agent | n2=en:triptorelin | rel=r_associated | relid=0 | w=26
  415. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:trpv6 calcium channel inhibitor sor-c13
    n1=en:antileukemic agent | n2=en:trpv6 calcium channel inhibitor sor-c13 | rel=r_associated | relid=0 | w=26
  416. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:urethane
    n1=en:antileukemic agent | n2=en:urethane | rel=r_associated | relid=0 | w=26
  417. en:antileukemic agent -- r_associated #0: 26 / 0.605 -> en:zinc finger nuclease zfn-603
    n1=en:antileukemic agent | n2=en:zinc finger nuclease zfn-603 | rel=r_associated | relid=0 | w=26
  418. en:antileukemic agent -- r_associated #0: 21 / 0.488 -> préparation pharmaceutique
    n1=en:antileukemic agent | n2=préparation pharmaceutique | rel=r_associated | relid=0 | w=21
  419. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> 5 FU
    n1=en:antileukemic agent | n2=5 FU | rel=r_associated | relid=0 | w=20
  420. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> additive
    n1=en:antileukemic agent | n2=additive | rel=r_associated | relid=0 | w=20
  421. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agent antinéoplasique
    n1=en:antileukemic agent | n2=agent antinéoplasique | rel=r_associated | relid=0 | w=20
  422. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agglutinine
    n1=en:antileukemic agent | n2=agglutinine | rel=r_associated | relid=0 | w=20
  423. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agoniste myelo ablatif
    n1=en:antileukemic agent | n2=agoniste myelo ablatif | rel=r_associated | relid=0 | w=20
  424. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agonistes myelo ablatifs
    n1=en:antileukemic agent | n2=agonistes myelo ablatifs | rel=r_associated | relid=0 | w=20
  425. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agonistes myélo-ablatifs
    n1=en:antileukemic agent | n2=agonistes myélo-ablatifs | rel=r_associated | relid=0 | w=20
  426. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agonistes myelo-ablatifs
    n1=en:antileukemic agent | n2=agonistes myelo-ablatifs | rel=r_associated | relid=0 | w=20
  427. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> agonistes myéloablatifs
    n1=en:antileukemic agent | n2=agonistes myéloablatifs | rel=r_associated | relid=0 | w=20
  428. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> alcoylant
    n1=en:antileukemic agent | n2=alcoylant | rel=r_associated | relid=0 | w=20
  429. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> alicament
    n1=en:antileukemic agent | n2=alicament | rel=r_associated | relid=0 | w=20
  430. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> alkylant
    n1=en:antileukemic agent | n2=alkylant | rel=r_associated | relid=0 | w=20
  431. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> antibiotique antineoplasique
    n1=en:antileukemic agent | n2=antibiotique antineoplasique | rel=r_associated | relid=0 | w=20
  432. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> antibiotique antinéoplasique
    n1=en:antileukemic agent | n2=antibiotique antinéoplasique | rel=r_associated | relid=0 | w=20
  433. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> antienzyme
    n1=en:antileukemic agent | n2=antienzyme | rel=r_associated | relid=0 | w=20
  434. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> antimétabolite
    n1=en:antileukemic agent | n2=antimétabolite | rel=r_associated | relid=0 | w=20
  435. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> antioestrogène synthétique
    n1=en:antileukemic agent | n2=antioestrogène synthétique | rel=r_associated | relid=0 | w=20
  436. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> asparaginase
    n1=en:antileukemic agent | n2=asparaginase | rel=r_associated | relid=0 | w=20
  437. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> bevacizumab
    n1=en:antileukemic agent | n2=bevacizumab | rel=r_associated | relid=0 | w=20
  438. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> busulfan
    n1=en:antileukemic agent | n2=busulfan | rel=r_associated | relid=0 | w=20
  439. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> cannabidiol
    n1=en:antileukemic agent | n2=cannabidiol | rel=r_associated | relid=0 | w=20
  440. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> carmustine
    n1=en:antileukemic agent | n2=carmustine | rel=r_associated | relid=0 | w=20
  441. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> ceritinib
    n1=en:antileukemic agent | n2=ceritinib | rel=r_associated | relid=0 | w=20
  442. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> cis-diaminedichloroplatine
    n1=en:antileukemic agent | n2=cis-diaminedichloroplatine | rel=r_associated | relid=0 | w=20
  443. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> cisplatine
    n1=en:antileukemic agent | n2=cisplatine | rel=r_associated | relid=0 | w=20
  444. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> composé de cisplatine
    n1=en:antileukemic agent | n2=composé de cisplatine | rel=r_associated | relid=0 | w=20
  445. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> cyclophosphamide
    n1=en:antileukemic agent | n2=cyclophosphamide | rel=r_associated | relid=0 | w=20
  446. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> cyprotérone
    n1=en:antileukemic agent | n2=cyprotérone | rel=r_associated | relid=0 | w=20
  447. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> diéthylstilbestrol
    n1=en:antileukemic agent | n2=diéthylstilbestrol | rel=r_associated | relid=0 | w=20
  448. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> diéthylstilboestrol
    n1=en:antileukemic agent | n2=diéthylstilboestrol | rel=r_associated | relid=0 | w=20
  449. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> élément déclencheur
    n1=en:antileukemic agent | n2=élément déclencheur | rel=r_associated | relid=0 | w=20
  450. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:2-fluorofucose-containing sgn-2ff
    n1=en:antileukemic agent | n2=en:2-fluorofucose-containing sgn-2ff | rel=r_associated | relid=0 | w=20
  451. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:antienzyme
    n1=en:antileukemic agent | n2=en:antienzyme | rel=r_associated | relid=0 | w=20
  452. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:antienzyme.
    n1=en:antileukemic agent | n2=en:antienzyme. | rel=r_associated | relid=0 | w=20
  453. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:antineoplastic protein inhibitor
    n1=en:antileukemic agent | n2=en:antineoplastic protein inhibitor | rel=r_associated | relid=0 | w=20
  454. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:antineoplastic radiopharmaceutical agent
    n1=en:antileukemic agent | n2=en:antineoplastic radiopharmaceutical agent | rel=r_associated | relid=0 | w=20
  455. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:apoptotic pathway-targeting antineoplastic agent
    n1=en:antileukemic agent | n2=en:apoptotic pathway-targeting antineoplastic agent | rel=r_associated | relid=0 | w=20
  456. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:binimetinib-containing product
    n1=en:antileukemic agent | n2=en:binimetinib-containing product | rel=r_associated | relid=0 | w=20
  457. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:busulphan
    n1=en:antileukemic agent | n2=en:busulphan | rel=r_associated | relid=0 | w=20
  458. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:cd47 antagonist alx148
    n1=en:antileukemic agent | n2=en:cd47 antagonist alx148 | rel=r_associated | relid=0 | w=20
  459. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:ceramide nanoliposome
    n1=en:antileukemic agent | n2=en:ceramide nanoliposome | rel=r_associated | relid=0 | w=20
  460. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:cisplatin/vinblastine/cell penetration enhancer formulation int230-6
    n1=en:antileukemic agent | n2=en:cisplatin/vinblastine/cell penetration enhancer formulation int230-6 | rel=r_associated | relid=0 | w=20
  461. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:demethylating agent
    n1=en:antileukemic agent | n2=en:demethylating agent | rel=r_associated | relid=0 | w=20
  462. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:epidermal growth factor receptor antagonist [epc]
    n1=en:antileukemic agent | n2=en:epidermal growth factor receptor antagonist [epc] | rel=r_associated | relid=0 | w=20
  463. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:fluoro-uracile
    n1=en:antileukemic agent | n2=en:fluoro-uracile | rel=r_associated | relid=0 | w=20
  464. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:gallium maltolate
    n1=en:antileukemic agent | n2=en:gallium maltolate | rel=r_associated | relid=0 | w=20
  465. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:game changer
    n1=en:antileukemic agent | n2=en:game changer | rel=r_associated | relid=0 | w=20
  466. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:hif-2alpha inhibitor pt2977
    n1=en:antileukemic agent | n2=en:hif-2alpha inhibitor pt2977 | rel=r_associated | relid=0 | w=20
  467. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:modified vitamin d binding protein macrophage activator ef-022
    n1=en:antileukemic agent | n2=en:modified vitamin d binding protein macrophage activator ef-022 | rel=r_associated | relid=0 | w=20
  468. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:motivating factor
    n1=en:antileukemic agent | n2=en:motivating factor | rel=r_associated | relid=0 | w=20
  469. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:nilandron
    n1=en:antileukemic agent | n2=en:nilandron | rel=r_associated | relid=0 | w=20
  470. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:orphan medication
    n1=en:antileukemic agent | n2=en:orphan medication | rel=r_associated | relid=0 | w=20
  471. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:orphan medicinal product
    n1=en:antileukemic agent | n2=en:orphan medicinal product | rel=r_associated | relid=0 | w=20
  472. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:p53-hdm2 protein-protein interaction inhibitor apg-115
    n1=en:antileukemic agent | n2=en:p53-hdm2 protein-protein interaction inhibitor apg-115 | rel=r_associated | relid=0 | w=20
  473. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:panobinostat lactate
    n1=en:antileukemic agent | n2=en:panobinostat lactate | rel=r_associated | relid=0 | w=20
  474. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:risperidone formulation in rumenic acid
    n1=en:antileukemic agent | n2=en:risperidone formulation in rumenic acid | rel=r_associated | relid=0 | w=20
  475. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:tgfbeta inhibitor ly3200882
    n1=en:antileukemic agent | n2=en:tgfbeta inhibitor ly3200882 | rel=r_associated | relid=0 | w=20
  476. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> en:urethan
    n1=en:antileukemic agent | n2=en:urethan | rel=r_associated | relid=0 | w=20
  477. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> enzalutamide
    n1=en:antileukemic agent | n2=enzalutamide | rel=r_associated | relid=0 | w=20
  478. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> finastéride
    n1=en:antileukemic agent | n2=finastéride | rel=r_associated | relid=0 | w=20
  479. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> fludarabine
    n1=en:antileukemic agent | n2=fludarabine | rel=r_associated | relid=0 | w=20
  480. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> fluoro-uracile
    n1=en:antileukemic agent | n2=fluoro-uracile | rel=r_associated | relid=0 | w=20
  481. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> gemcitabine
    n1=en:antileukemic agent | n2=gemcitabine | rel=r_associated | relid=0 | w=20
  482. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> inhibiteur d'enzymes
    n1=en:antileukemic agent | n2=inhibiteur d'enzymes | rel=r_associated | relid=0 | w=20
  483. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> inhibiteur de l'aromatase
    n1=en:antileukemic agent | n2=inhibiteur de l'aromatase | rel=r_associated | relid=0 | w=20
  484. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> inhibiteur de transduction du signal
    n1=en:antileukemic agent | n2=inhibiteur de transduction du signal | rel=r_associated | relid=0 | w=20
  485. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> inhibiteur enzymatique
    n1=en:antileukemic agent | n2=inhibiteur enzymatique | rel=r_associated | relid=0 | w=20
  486. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> inhibiteurs de l'aromatase
    n1=en:antileukemic agent | n2=inhibiteurs de l'aromatase | rel=r_associated | relid=0 | w=20
  487. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> ipilimumab
    n1=en:antileukemic agent | n2=ipilimumab | rel=r_associated | relid=0 | w=20
  488. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> irinotecan
    n1=en:antileukemic agent | n2=irinotecan | rel=r_associated | relid=0 | w=20
  489. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> médicament orphelin
    n1=en:antileukemic agent | n2=médicament orphelin | rel=r_associated | relid=0 | w=20
  490. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> médicament peu rentable
    n1=en:antileukemic agent | n2=médicament peu rentable | rel=r_associated | relid=0 | w=20
  491. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> modulateur sélectif des récepteurs ?strogéniques
    n1=en:antileukemic agent | n2=modulateur sélectif des récepteurs ?strogéniques | rel=r_associated | relid=0 | w=20
  492. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> olaparib
    n1=en:antileukemic agent | n2=olaparib | rel=r_associated | relid=0 | w=20
  493. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> palbociclib
    n1=en:antileukemic agent | n2=palbociclib | rel=r_associated | relid=0 | w=20
  494. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> piroxicam
    n1=en:antileukemic agent | n2=piroxicam | rel=r_associated | relid=0 | w=20
  495. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> procarbazine
    n1=en:antileukemic agent | n2=procarbazine | rel=r_associated | relid=0 | w=20
  496. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> produit nutraceutique
    n1=en:antileukemic agent | n2=produit nutraceutique | rel=r_associated | relid=0 | w=20
  497. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> produit nutriceutique
    n1=en:antileukemic agent | n2=produit nutriceutique | rel=r_associated | relid=0 | w=20
  498. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> ramucirumab
    n1=en:antileukemic agent | n2=ramucirumab | rel=r_associated | relid=0 | w=20
  499. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> rituximab
    n1=en:antileukemic agent | n2=rituximab | rel=r_associated | relid=0 | w=20
  500. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> ruxolitinib
    n1=en:antileukemic agent | n2=ruxolitinib | rel=r_associated | relid=0 | w=20
  501. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> spermicide
    n1=en:antileukemic agent | n2=spermicide | rel=r_associated | relid=0 | w=20
  502. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> temsirolimus
    n1=en:antileukemic agent | n2=temsirolimus | rel=r_associated | relid=0 | w=20
  503. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> thyrotropine alfa
    n1=en:antileukemic agent | n2=thyrotropine alfa | rel=r_associated | relid=0 | w=20
  504. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> trastuzumab
    n1=en:antileukemic agent | n2=trastuzumab | rel=r_associated | relid=0 | w=20
  505. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> uréthane
    n1=en:antileukemic agent | n2=uréthane | rel=r_associated | relid=0 | w=20
  506. en:antileukemic agent -- r_associated #0: 20 / 0.465 -> vinblastine
    n1=en:antileukemic agent | n2=vinblastine | rel=r_associated | relid=0 | w=20
≈ 631 relations entrantes

  1. en:antineoplastic agent --- r_associated #0: 310 --> en:antileukemic agent
    n1=en:antineoplastic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=310
  2. agent antinéoplasique --- r_associated #0: 308 --> en:antileukemic agent
    n1=agent antinéoplasique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=308
  3. agoniste myelo ablatif --- r_associated #0: 202 --> en:antileukemic agent
    n1=agoniste myelo ablatif | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=202
  4. agonistes myelo ablatifs --- r_associated #0: 200 --> en:antileukemic agent
    n1=agonistes myelo ablatifs | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=200
  5. en:myeloablative agonist --- r_associated #0: 200 --> en:antileukemic agent
    n1=en:myeloablative agonist | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=200
  6. inhibiteur de l'aromatase --- r_associated #0: 185 --> en:antileukemic agent
    n1=inhibiteur de l'aromatase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=185
  7. en:aromatase inhibitor --- r_associated #0: 182 --> en:antileukemic agent
    n1=en:aromatase inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=182
  8. agonistes myélo-ablatifs --- r_associated #0: 166 --> en:antileukemic agent
    n1=agonistes myélo-ablatifs | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=166
  9. agonistes myéloablatifs --- r_associated #0: 162 --> en:antileukemic agent
    n1=agonistes myéloablatifs | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=162
  10. en:antineoplastic antibiotic --- r_associated #0: 114 --> en:antileukemic agent
    n1=en:antineoplastic antibiotic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=114
  11. antibiotique antinéoplasique --- r_associated #0: 112 --> en:antileukemic agent
    n1=antibiotique antinéoplasique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=112
  12. en:ipilimumab --- r_associated #0: 108 --> en:antileukemic agent
    n1=en:ipilimumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=108
  13. ipilimumab --- r_associated #0: 104 --> en:antileukemic agent
    n1=ipilimumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=104
  14. cyprotérone --- r_associated #0: 96 --> en:antileukemic agent
    n1=cyprotérone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=96
  15. en:cyproterone --- r_associated #0: 95 --> en:antileukemic agent
    n1=en:cyproterone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=95
  16. cis-diaminedichloroplatine --- r_associated #0: 91 --> en:antileukemic agent
    n1=cis-diaminedichloroplatine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=91
  17. en:diethylstilbestrol --- r_associated #0: 90 --> en:antileukemic agent
    n1=en:diethylstilbestrol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=90
  18. uréthane --- r_associated #0: 90 --> en:antileukemic agent
    n1=uréthane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=90
  19. en:cisplatin --- r_associated #0: 88 --> en:antileukemic agent
    n1=en:cisplatin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=88
  20. en:urethane --- r_associated #0: 88 --> en:antileukemic agent
    n1=en:urethane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=88
  21. cisplatine --- r_associated #0: 86 --> en:antileukemic agent
    n1=cisplatine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=86
  22. diéthylstilbestrol --- r_associated #0: 86 --> en:antileukemic agent
    n1=diéthylstilbestrol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=86
  23. procarbazine --- r_associated #0: 85 --> en:antileukemic agent
    n1=procarbazine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=85
  24. cannabidiol --- r_associated #0: 82 --> en:antileukemic agent
    n1=cannabidiol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=82
  25. en:procarbazine --- r_associated #0: 82 --> en:antileukemic agent
    n1=en:procarbazine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=82
  26. en:cannabidiol --- r_associated #0: 80 --> en:antileukemic agent
    n1=en:cannabidiol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=80
  27. asparaginase --- r_associated #0: 76 --> en:antileukemic agent
    n1=asparaginase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=76
  28. en:palbociclib --- r_associated #0: 75 --> en:antileukemic agent
    n1=en:palbociclib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=75
  29. inhibiteur enzymatique --- r_associated #0: 74 --> en:antileukemic agent
    n1=inhibiteur enzymatique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=74
  30. busulfan --- r_associated #0: 73 --> en:antileukemic agent
    n1=busulfan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=73
  31. carmustine --- r_associated #0: 73 --> en:antileukemic agent
    n1=carmustine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=73
  32. cyclophosphamide --- r_associated #0: 73 --> en:antileukemic agent
    n1=cyclophosphamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=73
  33. en:asparaginase --- r_associated #0: 72 --> en:antileukemic agent
    n1=en:asparaginase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=72
  34. palbociclib --- r_associated #0: 72 --> en:antileukemic agent
    n1=palbociclib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=72
  35. en:busulfan --- r_associated #0: 71 --> en:antileukemic agent
    n1=en:busulfan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=71
  36. en:carmustine --- r_associated #0: 71 --> en:antileukemic agent
    n1=en:carmustine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=71
  37. en:enzyme inhibitor --- r_associated #0: 71 --> en:antileukemic agent
    n1=en:enzyme inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=71
  38. médicament orphelin --- r_associated #0: 71 --> en:antileukemic agent
    n1=médicament orphelin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=71
  39. en:fludarabine --- r_associated #0: 70 --> en:antileukemic agent
    n1=en:fludarabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=70
  40. en:spermicide --- r_associated #0: 70 --> en:antileukemic agent
    n1=en:spermicide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=70
  41. en:urethan --- r_associated #0: 70 --> en:antileukemic agent
    n1=en:urethan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=70
  42. inhibiteur d'enzymes --- r_associated #0: 70 --> en:antileukemic agent
    n1=inhibiteur d'enzymes | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=70
  43. en:cyclophosphamide --- r_associated #0: 69 --> en:antileukemic agent
    n1=en:cyclophosphamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=69
  44. fludarabine --- r_associated #0: 68 --> en:antileukemic agent
    n1=fludarabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=68
  45. spermicide --- r_associated #0: 68 --> en:antileukemic agent
    n1=spermicide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=68
  46. en:orphan drug --- r_associated #0: 67 --> en:antileukemic agent
    n1=en:orphan drug | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=67
  47. antienzyme --- r_associated #0: 65 --> en:antileukemic agent
    n1=antienzyme | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=65
  48. en:temsirolimus --- r_associated #0: 65 --> en:antileukemic agent
    n1=en:temsirolimus | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=65
  49. rituximab --- r_associated #0: 65 --> en:antileukemic agent
    n1=rituximab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=65
  50. en:rituximab --- r_associated #0: 64 --> en:antileukemic agent
    n1=en:rituximab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=64
  51. temsirolimus --- r_associated #0: 63 --> en:antileukemic agent
    n1=temsirolimus | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=63
  52. en:olaparib --- r_associated #0: 59 --> en:antileukemic agent
    n1=en:olaparib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=59
  53. composé de cisplatine --- r_associated #0: 57 --> en:antileukemic agent
    n1=composé de cisplatine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=57
  54. en:piroxicam --- r_associated #0: 56 --> en:antileukemic agent
    n1=en:piroxicam | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=56
  55. piroxicam --- r_associated #0: 56 --> en:antileukemic agent
    n1=piroxicam | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=56
  56. inhibiteur de transduction du signal --- r_associated #0: 55 --> en:antileukemic agent
    n1=inhibiteur de transduction du signal | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=55
  57. olaparib --- r_associated #0: 55 --> en:antileukemic agent
    n1=olaparib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=55
  58. en:trastuzumab --- r_associated #0: 54 --> en:antileukemic agent
    n1=en:trastuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=54
  59. en:gemcitabine --- r_associated #0: 53 --> en:antileukemic agent
    n1=en:gemcitabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=53
  60. vinblastine --- r_associated #0: 52 --> en:antileukemic agent
    n1=vinblastine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=52
  61. en:signal transduction inhibitor --- r_associated #0: 51 --> en:antileukemic agent
    n1=en:signal transduction inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=51
  62. en:thyrotropin alfa --- r_associated #0: 50 --> en:antileukemic agent
    n1=en:thyrotropin alfa | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=50
  63. gemcitabine --- r_associated #0: 50 --> en:antileukemic agent
    n1=gemcitabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=50
  64. trastuzumab --- r_associated #0: 50 --> en:antileukemic agent
    n1=trastuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=50
  65. en:vinblastine --- r_associated #0: 49 --> en:antileukemic agent
    n1=en:vinblastine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=49
  66. thyrotropine alfa --- r_associated #0: 49 --> en:antileukemic agent
    n1=thyrotropine alfa | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=49
  67. en:synthetic antiestrogen --- r_associated #0: 46 --> en:antileukemic agent
    n1=en:synthetic antiestrogen | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=46
  68. antibiotique antineoplasique --- r_associated #0: 44 --> en:antileukemic agent
    n1=antibiotique antineoplasique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=44
  69. antioestrogène synthétique --- r_associated #0: 44 --> en:antileukemic agent
    n1=antioestrogène synthétique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=44
  70. en:ozone-based agent --- r_associated #0: 42 --> en:antileukemic agent
    n1=en:ozone-based agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=42
  71. en:alpha-gal glycosphingolipids --- r_associated #0: 41 --> en:antileukemic agent
    n1=en:alpha-gal glycosphingolipids | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=41
  72. en:apoptosis inducer mpc-2130 --- r_associated #0: 41 --> en:antileukemic agent
    n1=en:apoptosis inducer mpc-2130 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=41
  73. en:carboxyamidotriazole orotate --- r_associated #0: 41 --> en:antileukemic agent
    n1=en:carboxyamidotriazole orotate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=41
  74. inhibiteurs de l'aromatase --- r_associated #0: 40 --> en:antileukemic agent
    n1=inhibiteurs de l'aromatase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=40
  75. en:alpha-tocopheryloxyacetic acid --- r_associated #0: 39 --> en:antileukemic agent
    n1=en:alpha-tocopheryloxyacetic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=39
  76. en:asp4132 --- r_associated #0: 39 --> en:antileukemic agent
    n1=en:asp4132 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=39
  77. en:tretazicar --- r_associated #0: 39 --> en:antileukemic agent
    n1=en:tretazicar | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=39
  78. en:erastin analogue prlx 93936 --- r_associated #0: 38 --> en:antileukemic agent
    n1=en:erastin analogue prlx 93936 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=38
  79. fluoro-uracile --- r_associated #0: 38 --> en:antileukemic agent
    n1=fluoro-uracile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=38
  80. en:antipneumocystis agent --- r_associated #0: 37 --> en:antileukemic agent
    n1=en:antipneumocystis agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=37
  81. en:epipropidine --- r_associated #0: 37 --> en:antileukemic agent
    n1=en:epipropidine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=37
  82. en:2-fluorofucose-containing sgn-2ff --- r_associated #0: 36 --> en:antileukemic agent
    n1=en:2-fluorofucose-containing sgn-2ff | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=36
  83. en:antineoplastic vinca alkaloid --- r_associated #0: 36 --> en:antileukemic agent
    n1=en:antineoplastic vinca alkaloid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=36
  84. en:tigapotide --- r_associated #0: 36 --> en:antileukemic agent
    n1=en:tigapotide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=36
  85. Agglutinine --- r_associated #0: 35 --> en:antileukemic agent
    n1=Agglutinine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  86. agglutinine --- r_associated #0: 35 --> en:antileukemic agent
    n1=agglutinine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  87. antimétabolite --- r_associated #0: 35 --> en:antileukemic agent
    n1=antimétabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  88. en:agglutinin --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:agglutinin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  89. en:amidino tic --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:amidino tic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  90. en:antimetabolite --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:antimetabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  91. en:antineoplastic adjuvants --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:antineoplastic adjuvants | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  92. en:apoptotic pathway-targeting antineoplastic agent --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:apoptotic pathway-targeting antineoplastic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  93. en:artemether sublingual spray --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:artemether sublingual spray | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  94. en:bryostatin 1 --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:bryostatin 1 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  95. en:caricotamide/tretazicar --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:caricotamide/tretazicar | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  96. en:ceramide nanoliposome --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:ceramide nanoliposome | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  97. en:dimethyl sulfoxide --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:dimethyl sulfoxide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  98. en:elotuzumab --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:elotuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  99. en:factor viia inhibitor pci-27483 --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:factor viia inhibitor pci-27483 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  100. en:ingenol mebutate gel --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:ingenol mebutate gel | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  101. en:interleukin inhibitor --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:interleukin inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  102. en:lactoferrin-derived lytic peptide ltx-315 --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:lactoferrin-derived lytic peptide ltx-315 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  103. en:mitoquidone --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:mitoquidone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  104. en:obatoclax --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:obatoclax | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  105. en:ramucirumab --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:ramucirumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  106. en:tasisulam --- r_associated #0: 35 --> en:antileukemic agent
    n1=en:tasisulam | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  107. ramucirumab --- r_associated #0: 35 --> en:antileukemic agent
    n1=ramucirumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=35
  108. agonistes myelo-ablatifs --- r_associated #0: 34 --> en:antileukemic agent
    n1=agonistes myelo-ablatifs | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  109. en:additive --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:additive | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  110. en:adjunct agent --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:adjunct agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  111. en:antiapoptotic agent --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:antiapoptotic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  112. en:anticarcinogenic agents --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:anticarcinogenic agents | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  113. en:antineoplastic agents, phytogenic --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:antineoplastic agents, phytogenic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  114. en:antineoplastic radiopharmaceutical agent --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:antineoplastic radiopharmaceutical agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  115. en:beta-lapachone prodrug arq 761 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:beta-lapachone prodrug arq 761 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  116. en:bicalutamide --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:bicalutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  117. en:catalyst --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:catalyst | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  118. en:cedefingol --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:cedefingol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  119. en:elesclomol --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:elesclomol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  120. en:ep4 receptor antagonist aat-007 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:ep4 receptor antagonist aat-007 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  121. en:fluorouracil --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:fluorouracil | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  122. en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  123. en:galectin inhibitor gr-md-02 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:galectin inhibitor gr-md-02 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  124. en:haemato fu --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:haemato fu | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  125. en:ibritumomab --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:ibritumomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  126. en:irinotecan --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:irinotecan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  127. en:leuprolide --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:leuprolide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  128. en:monoclonal antibodies, antineoplastic --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:monoclonal antibodies, antineoplastic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  129. en:pegylated human recombinant arginase 1 aeb1102 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:pegylated human recombinant arginase 1 aeb1102 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  130. en:polyamine analogue --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:polyamine analogue | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  131. en:prohibitin-targeting peptide 1 --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:prohibitin-targeting peptide 1 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  132. en:protocol agent --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:protocol agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  133. en:psychotropic agent --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:psychotropic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  134. en:teglarinad --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:teglarinad | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  135. en:thioureidobutyronitrile --- r_associated #0: 34 --> en:antileukemic agent
    n1=en:thioureidobutyronitrile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  136. fluorouracile --- r_associated #0: 34 --> en:antileukemic agent
    n1=fluorouracile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  137. irinotecan --- r_associated #0: 34 --> en:antileukemic agent
    n1=irinotecan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  138. modulateur sélectif des récepteurs ?strogéniques --- r_associated #0: 34 --> en:antileukemic agent
    n1=modulateur sélectif des récepteurs ?strogéniques | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  139. élément déclencheur --- r_associated #0: 34 --> en:antileukemic agent
    n1=élément déclencheur | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=34
  140. en:anti-vegf anticalin prs-050-peg40 --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:anti-vegf anticalin prs-050-peg40 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  141. en:antineoplastic metal complex agent --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:antineoplastic metal complex agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  142. en:apoptosis inducer bzl101 --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:apoptosis inducer bzl101 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  143. en:bexarotene --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:bexarotene | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  144. en:chlorotoxin [131i] --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:chlorotoxin [131i] | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  145. en:cinobufagin --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:cinobufagin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  146. en:compound kushen injection --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:compound kushen injection | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  147. en:cytostatic agents --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:cytostatic agents | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  148. en:epidermal growth factor receptor tyrosine kinase inhibitor --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:epidermal growth factor receptor tyrosine kinase inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  149. en:forodesine --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:forodesine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  150. en:hif-2alpha inhibitor pt2977 --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:hif-2alpha inhibitor pt2977 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  151. en:ingenol mebutate --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:ingenol mebutate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  152. en:metaiodobenzylguanidine[131i] --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:metaiodobenzylguanidine[131i] | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  153. en:naptumomab --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:naptumomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  154. en:nucleolin antagonist ipp-204106n --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:nucleolin antagonist ipp-204106n | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  155. en:poly (adp-ribose) polymerase inhibitor --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:poly (adp-ribose) polymerase inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  156. en:selective estrogen receptor modulator --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:selective estrogen receptor modulator | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  157. en:stressor --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:stressor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  158. en:topoisomerase inhibitor --- r_associated #0: 32 --> en:antileukemic agent
    n1=en:topoisomerase inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=32
  159. diéthylstilboestrol --- r_associated #0: 31 --> en:antileukemic agent
    n1=diéthylstilboestrol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  160. en:ambazone --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:ambazone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  161. en:amphotericin product --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:amphotericin product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  162. en:antineoplastic agents, hormonal --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:antineoplastic agents, hormonal | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  163. en:carbohydrate processing inhibitor --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:carbohydrate processing inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  164. en:catumaxomab --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:catumaxomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  165. en:cephalostatin --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:cephalostatin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  166. en:everolimus --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:everolimus | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  167. en:galectin-1 inhibitor otx008 --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:galectin-1 inhibitor otx008 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  168. en:huachansu --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:huachansu | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  169. en:intiquinatine --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:intiquinatine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  170. en:metabolite --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:metabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  171. en:nutlin-3a --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:nutlin-3a | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  172. en:odorant --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:odorant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  173. en:p53-hdm2 protein-protein interaction inhibitor apg-115 --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:p53-hdm2 protein-protein interaction inhibitor apg-115 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  174. en:pleiotropic pathway modifier cc-122 hydrochloride --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:pleiotropic pathway modifier cc-122 hydrochloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  175. en:sensitive anticancer agent --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:sensitive anticancer agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  176. en:verteporfin --- r_associated #0: 31 --> en:antileukemic agent
    n1=en:verteporfin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=31
  177. additive --- r_associated #0: 30 --> en:antileukemic agent
    n1=additive | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  178. bevacizumab --- r_associated #0: 30 --> en:antileukemic agent
    n1=bevacizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  179. ceritinib --- r_associated #0: 30 --> en:antileukemic agent
    n1=ceritinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  180. en:abarelix --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:abarelix | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  181. en:alectinib --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:alectinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  182. en:alvocidib hydrochloride --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:alvocidib hydrochloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  183. en:benaxibine --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:benaxibine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  184. en:bet inhibitor --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:bet inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  185. en:bevacizumab --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:bevacizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  186. en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  187. en:braf inhibitor --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:braf inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  188. en:busulphan --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:busulphan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  189. en:cd47 antagonist alx148 --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:cd47 antagonist alx148 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  190. en:ceritinib --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:ceritinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  191. en:cytoprotective agent --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:cytoprotective agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  192. en:darinaparsin --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:darinaparsin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  193. en:demethylating agent --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:demethylating agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  194. en:dopamine-somatostatin chimeric molecule bim-23a760 --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:dopamine-somatostatin chimeric molecule bim-23a760 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  195. en:elesclomol sodium --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:elesclomol sodium | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  196. en:enteric-coated trpm8 agonist d-3263 hydrochloride --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:enteric-coated trpm8 agonist d-3263 hydrochloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  197. en:game changer --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:game changer | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  198. en:non-cytotoxic agent --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:non-cytotoxic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  199. en:nutraceutical --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:nutraceutical | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  200. en:over the counter product --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:over the counter product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  201. en:prima-1 analog apr-246 --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:prima-1 analog apr-246 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  202. en:terfluranol --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:terfluranol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  203. en:zanolimumab --- r_associated #0: 30 --> en:antileukemic agent
    n1=en:zanolimumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  204. produit nutraceutique --- r_associated #0: 30 --> en:antileukemic agent
    n1=produit nutraceutique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  205. produit nutriceutique --- r_associated #0: 30 --> en:antileukemic agent
    n1=produit nutriceutique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=30
  206. alcoylant --- r_associated #0: 29 --> en:antileukemic agent
    n1=alcoylant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  207. alkylant --- r_associated #0: 29 --> en:antileukemic agent
    n1=alkylant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  208. en:antagonist --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:antagonist | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  209. en:antineoplastic agent combination sm-88 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:antineoplastic agent combination sm-88 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  210. en:antineoplastic agent trx-818 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:antineoplastic agent trx-818 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  211. en:cycle-phase nonspecific agent --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:cycle-phase nonspecific agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  212. en:epothilone compound --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:epothilone compound | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  213. en:ibritumomab tiuxetan --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:ibritumomab tiuxetan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  214. en:illicit substance --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:illicit substance | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  215. en:kanglaite --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:kanglaite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  216. en:modified vitamin d binding protein macrophage activator ef-022 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:modified vitamin d binding protein macrophage activator ef-022 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  217. en:plevitrexed --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:plevitrexed | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  218. en:proteasome inhibitor --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:proteasome inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  219. en:risperidone formulation in rumenic acid --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:risperidone formulation in rumenic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  220. en:splicing inhibitor h3b-8800 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:splicing inhibitor h3b-8800 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  221. en:tasisulam sodium --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:tasisulam sodium | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  222. en:tositumomab --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:tositumomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  223. en:tyroserleutide --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:tyroserleutide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  224. en:zinc finger nuclease zfn-603 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:zinc finger nuclease zfn-603 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  225. en:zinc finger nuclease zfn-758 --- r_associated #0: 29 --> en:antileukemic agent
    n1=en:zinc finger nuclease zfn-758 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  226. médicament peu rentable --- r_associated #0: 29 --> en:antileukemic agent
    n1=médicament peu rentable | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=29
  227. 5 FU --- r_associated #0: 28 --> en:antileukemic agent
    n1=5 FU | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  228. Inhibiteur enzymatique --- r_associated #0: 28 --> en:antileukemic agent
    n1=Inhibiteur enzymatique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  229. alicament --- r_associated #0: 28 --> en:antileukemic agent
    n1=alicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  230. en:2-hydroxyoleic acid --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:2-hydroxyoleic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  231. en:alkylating agent --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:alkylating agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  232. en:anti-pkn3 sirna atu027 --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:anti-pkn3 sirna atu027 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  233. en:antienzyme --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:antienzyme | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  234. en:antienzyme. --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:antienzyme. | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  235. en:antimetastatic agent --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:antimetastatic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  236. en:antineoplastic anthraquinone --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:antineoplastic anthraquinone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  237. en:azapicyl --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:azapicyl | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  238. en:bc-819 plasmid/polyethylenimine complex --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:bc-819 plasmid/polyethylenimine complex | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  239. en:beta-elemene --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:beta-elemene | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  240. en:bromacrylide --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:bromacrylide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  241. en:cebpa-targeting sarna mtl-cebpa liposome --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:cebpa-targeting sarna mtl-cebpa liposome | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  242. en:clanfenur --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:clanfenur | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  243. en:e-selectin antagonist gmi-1271 --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:e-selectin antagonist gmi-1271 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  244. en:finasteride --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:finasteride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  245. en:giracodazole --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:giracodazole | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  246. en:jin fu kang --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:jin fu kang | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  247. en:mcl-1 inhibitor amg 176 --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:mcl-1 inhibitor amg 176 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  248. en:nanoparticle-targeted drug --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:nanoparticle-targeted drug | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  249. en:nintedanib --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:nintedanib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  250. en:phosphaplatin pt-112 --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:phosphaplatin pt-112 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  251. en:pre-medication --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:pre-medication | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  252. en:tgfbeta inhibitor ly3200882 --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:tgfbeta inhibitor ly3200882 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  253. en:tolnidamine --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:tolnidamine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  254. en:yangzheng xiaoji extract --- r_associated #0: 28 --> en:antileukemic agent
    n1=en:yangzheng xiaoji extract | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  255. finastéride --- r_associated #0: 28 --> en:antileukemic agent
    n1=finastéride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=28
  256. en:belinostat --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:belinostat | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  257. en:bh3 mimetic abt-737 --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:bh3 mimetic abt-737 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  258. en:breflate --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:breflate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  259. en:cancell --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:cancell | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  260. en:digestant --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:digestant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  261. en:disinfectant --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:disinfectant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  262. en:dta-h19 plasmid --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:dta-h19 plasmid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  263. en:enzalutamide --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:enzalutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  264. en:gallium maltolate --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:gallium maltolate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  265. en:harringtonines --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:harringtonines | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  266. en:iap inhibitor hgs1029 --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:iap inhibitor hgs1029 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  267. en:inproquone --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:inproquone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  268. en:intravesical bcg --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:intravesical bcg | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  269. en:lapachone --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:lapachone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  270. en:orphan medication --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:orphan medication | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  271. en:pharmaceutical excipient --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:pharmaceutical excipient | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  272. en:pol i inhibitor cx5461 --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:pol i inhibitor cx5461 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  273. en:polyamine synthesis inhibitor --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:polyamine synthesis inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  274. en:simtrazene --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:simtrazene | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  275. en:talimogene laherparepvec --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:talimogene laherparepvec | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  276. en:topical betulinic acid --- r_associated #0: 27 --> en:antileukemic agent
    n1=en:topical betulinic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  277. enzalutamide --- r_associated #0: 27 --> en:antileukemic agent
    n1=enzalutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=27
  278. en:acivicin --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:acivicin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  279. en:anti-nucleolin aptamer as1411 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:anti-nucleolin aptamer as1411 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  280. en:antineoplastic protein inhibitor --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:antineoplastic protein inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  281. en:asp9853 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:asp9853 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  282. en:atr-101 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:atr-101 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  283. en:azurin:50-77 cell penetrating peptide p28 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:azurin:50-77 cell penetrating peptide p28 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  284. en:bcl-2 inhibitor bcl201 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:bcl-2 inhibitor bcl201 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  285. en:binimetinib-containing product --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:binimetinib-containing product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  286. en:birinapant --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:birinapant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  287. en:budotitane --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:budotitane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  288. en:cell differentiating agent --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:cell differentiating agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  289. en:chk1 inhibitor gdc-0425 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:chk1 inhibitor gdc-0425 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  290. en:cisplatin/vinblastine/cell penetration enhancer formulation int230-6 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:cisplatin/vinblastine/cell penetration enhancer formulation int230-6 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  291. en:ck2-targeting synthetic peptide cigb-300 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:ck2-targeting synthetic peptide cigb-300 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  292. en:cytokine agent --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:cytokine agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  293. en:diarylsulfonylurea compound --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:diarylsulfonylurea compound | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  294. en:dna-rna transcription regulator --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:dna-rna transcription regulator | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  295. en:epidermal growth factor receptor antagonist [epc] --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:epidermal growth factor receptor antagonist [epc] | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  296. en:fluoro-uracile --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:fluoro-uracile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  297. en:hypoxia-activated prodrug th-302 --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:hypoxia-activated prodrug th-302 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  298. en:medication --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:medication | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  299. en:motivating factor --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:motivating factor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  300. en:nilandron --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:nilandron | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  301. en:orphan medicinal product --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:orphan medicinal product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  302. en:panobinostat lactate --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:panobinostat lactate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  303. en:pegylated recombinant l-asparaginase erwinia chrysanthemi --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:pegylated recombinant l-asparaginase erwinia chrysanthemi | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  304. en:personal care product --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:personal care product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  305. en:radiosensitizing agent --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:radiosensitizing agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  306. en:retinoic acid agent --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:retinoic acid agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  307. en:ruxolitinib --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:ruxolitinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  308. en:synthesis inhibitors, dna --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:synthesis inhibitors, dna | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  309. en:taurultam --- r_associated #0: 26 --> en:antileukemic agent
    n1=en:taurultam | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  310. préparation pharmaceutique --- r_associated #0: 26 --> en:antileukemic agent
    n1=préparation pharmaceutique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  311. ruxolitinib --- r_associated #0: 26 --> en:antileukemic agent
    n1=ruxolitinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=26
  312. Ruxolitinib --- r_associated #0: 25 --> en:antileukemic agent
    n1=Ruxolitinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=25
  313. auxiliaire technologique --- r_associated #0: 23 --> en:antileukemic agent
    n1=auxiliaire technologique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=23
  314. BSQV --- r_associated #0: 22 --> en:antileukemic agent
    n1=BSQV | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=22
  315. en:Ruxolitinib --- r_associated #0: 22 --> en:antileukemic agent
    n1=en:Ruxolitinib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=22
  316. en:cisplatinum --- r_associated #0: 22 --> en:antileukemic agent
    n1=en:cisplatinum | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=22
  317. adversaire --- r_associated #0: 21 --> en:antileukemic agent
    n1=adversaire | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=21
  318. métabolite --- r_associated #0: 21 --> en:antileukemic agent
    n1=métabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=21
  319. Temsirolimus --- r_associated #0: 20 --> en:antileukemic agent
    n1=Temsirolimus | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  320. Trastuzumab --- r_associated #0: 20 --> en:antileukemic agent
    n1=Trastuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  321. en:ad5-cmv-nis --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:ad5-cmv-nis | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  322. en:adenosine a3 receptor agonist cf102 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:adenosine a3 receptor agonist cf102 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  323. en:alemtuzumab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:alemtuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  324. en:alloxan --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:alloxan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  325. en:aminoglutethimide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:aminoglutethimide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  326. en:aminolevulinic acid --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:aminolevulinic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  327. en:aminopterin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:aminopterin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  328. en:amsacrine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:amsacrine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  329. en:angiogenesis inhibitor --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:angiogenesis inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  330. en:anti-androgen --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:anti-androgen | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  331. en:anti-ksp/anti-vegf sirnas aln-vsp02 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:anti-ksp/anti-vegf sirnas aln-vsp02 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  332. en:anti-transthyretin sirna aln-ttr02 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:anti-transthyretin sirna aln-ttr02 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  333. en:antiestrogen --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antiestrogen | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  334. en:antimetabolite chemotherapy --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antimetabolite chemotherapy | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  335. en:antimitotic agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antimitotic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  336. en:antineoplastic alkaloid --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastic alkaloid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  337. en:antineoplastic alkylating agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastic alkylating agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  338. en:antineoplastic hormones --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastic hormones | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  339. en:antineoplastic metal complex preparation --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastic metal complex preparation | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  340. en:antineoplastic radiopharmaceuticals --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastic radiopharmaceuticals | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  341. en:antineoplastics, other --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:antineoplastics, other | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  342. en:apoptosis inducer gcs-100 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:apoptosis inducer gcs-100 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  343. en:aromatase inhibitors, 3rd generation --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:aromatase inhibitors, 3rd generation | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  344. en:arsenic --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:arsenic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  345. en:azacitidine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:azacitidine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  346. en:bcg vaccine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:bcg vaccine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  347. en:blinatumomab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:blinatumomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  348. en:boron delivery agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:boron delivery agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  349. en:brentuximab vedotin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:brentuximab vedotin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  350. en:bromodomain inhibitor abbv-075 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:bromodomain inhibitor abbv-075 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  351. en:bulk-forming agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:bulk-forming agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  352. en:calculus bovis/moschus/olibanum/myrrha capsule --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:calculus bovis/moschus/olibanum/myrrha capsule | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  353. en:calusterone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:calusterone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  354. en:camptothecin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:camptothecin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  355. en:cd5789 cream --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:cd5789 cream | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  356. en:chemotherapeutic topical agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:chemotherapeutic topical agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  357. en:chlorambucil --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:chlorambucil | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  358. en:cladribine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:cladribine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  359. en:concomitant agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:concomitant agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  360. en:cxcr4 peptide antagonist ly2510924 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:cxcr4 peptide antagonist ly2510924 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  361. en:cycle-phase specific agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:cycle-phase specific agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  362. en:cytotoxic agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:cytotoxic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  363. en:dacarbazine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:dacarbazine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  364. en:daratumumab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:daratumumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  365. en:dexanabinol --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:dexanabinol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  366. en:dihydrolenperone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:dihydrolenperone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  367. en:dna binding agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:dna binding agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  368. en:e2f1 pathway activator arq 171 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:e2f1 pathway activator arq 171 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  369. en:eflornithine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:eflornithine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  370. en:embolic agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:embolic agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  371. en:epha2-targeting dopc-encapsulated sirna --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:epha2-targeting dopc-encapsulated sirna | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  372. en:erythrocyte-encapsulated l-asparaginase suspension --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:erythrocyte-encapsulated l-asparaginase suspension | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  373. en:etidronate-cytarabine conjugate mbc-11 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:etidronate-cytarabine conjugate mbc-11 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  374. en:etoposide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:etoposide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  375. en:ets-family transcription factor inhibitor tk216 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:ets-family transcription factor inhibitor tk216 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  376. en:fact complex-targeting curaxin cbl0137 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fact complex-targeting curaxin cbl0137 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  377. en:fazarabine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fazarabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  378. en:fenretinide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fenretinide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  379. en:fermented soybean protein beverage --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fermented soybean protein beverage | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  380. en:fgf receptor antagonist hgs1036 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fgf receptor antagonist hgs1036 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  381. en:finished pharmaceutical product --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:finished pharmaceutical product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  382. en:floxuridine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:floxuridine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  383. en:flutamide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:flutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  384. en:fosquidone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:fosquidone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  385. en:functional food --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:functional food | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  386. en:gallium nitrate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:gallium nitrate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  387. en:gamboge resin extract tsb-9-w1 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:gamboge resin extract tsb-9-w1 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  388. en:gemtuzumab ozogamicin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:gemtuzumab ozogamicin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  389. en:generic drug --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:generic drug | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  390. en:glucocorticoid receptor antagonist cort125134 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:glucocorticoid receptor antagonist cort125134 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  391. en:glutathione disulfide nov-002 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:glutathione disulfide nov-002 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  392. en:hafnium oxide-containing nanoparticles nbtxr3 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hafnium oxide-containing nanoparticles nbtxr3 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  393. en:hdm2 antagonist jnj-26854165 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hdm2 antagonist jnj-26854165 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  394. en:hdm2 inhibitor hdm201 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hdm2 inhibitor hdm201 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  395. en:hdm2 inhibitor mk-8242 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hdm2 inhibitor mk-8242 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  396. en:heat shock protein inhibitor --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:heat shock protein inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  397. en:heparan sulfate glycosaminoglycan mimetic m402 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:heparan sulfate glycosaminoglycan mimetic m402 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  398. en:hif-1alpha inhibitor px-478 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hif-1alpha inhibitor px-478 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  399. en:hif-2alpha inhibitor pt2385 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hif-2alpha inhibitor pt2385 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  400. en:huaier extract granule --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:huaier extract granule | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  401. en:hydroxyurea --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:hydroxyurea | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  402. en:iap inhibitor at-406 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:iap inhibitor at-406 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  403. en:idasanutlin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:idasanutlin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  404. en:idelalisib --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:idelalisib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  405. en:ifosfamide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:ifosfamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  406. en:imiquimod --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:imiquimod | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  407. en:immunomodulating agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:immunomodulating agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  408. en:investigational new drug --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:investigational new drug | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  409. en:lenalidomide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:lenalidomide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  410. en:lipid encapsulated anti-plk1 sirna tkm-plk1 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:lipid encapsulated anti-plk1 sirna tkm-plk1 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  411. en:liposome-encapsulated mir-34 mimic mrx34 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:liposome-encapsulated mir-34 mimic mrx34 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  412. en:lomustine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:lomustine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  413. en:lsd1 inhibitor gsk2879552 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:lsd1 inhibitor gsk2879552 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  414. en:lysine-specific demethylase 1 inhibitor incb059872 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:lysine-specific demethylase 1 inhibitor incb059872 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  415. en:maltose tetrapalmitate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:maltose tetrapalmitate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  416. en:mdm2 antagonist ro5045337 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mdm2 antagonist ro5045337 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  417. en:mdm2 antagonist ro6839921 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mdm2 antagonist ro6839921 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  418. en:mdm2 inhibitor amg-232 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mdm2 inhibitor amg-232 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  419. en:mdm2 inhibitor ds-3032b --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mdm2 inhibitor ds-3032b | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  420. en:mdm2/mdmx inhibitor alrn-6924 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mdm2/mdmx inhibitor alrn-6924 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  421. en:mechlorethamine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mechlorethamine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  422. en:megestrol --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:megestrol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  423. en:melphalan --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:melphalan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  424. en:mercuric cyanide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mercuric cyanide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  425. en:methotrexate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:methotrexate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  426. en:methoxyamine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:methoxyamine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  427. en:methoxyamine hydrochloride --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:methoxyamine hydrochloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  428. en:miltefosine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:miltefosine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  429. en:mipsagargin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mipsagargin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  430. en:mitoxantrone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mitoxantrone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  431. en:molecular target inhibitors --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:molecular target inhibitors | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  432. en:monocarboxylate transporter 1 inhibitor azd3965 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:monocarboxylate transporter 1 inhibitor azd3965 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  433. en:morinda citrifolia fruit extract --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:morinda citrifolia fruit extract | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  434. en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  435. en:mutant p53 activator coti-2 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mutant p53 activator coti-2 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  436. en:myc-targeting sirna dcr-myc --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:myc-targeting sirna dcr-myc | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  437. en:mycobacterial cell wall-dna complex --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:mycobacterial cell wall-dna complex | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  438. en:nanocell-encapsulated mir-16-based microrna mimic --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:nanocell-encapsulated mir-16-based microrna mimic | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  439. en:napabucasin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:napabucasin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  440. en:nilutamide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:nilutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  441. en:obatoclax mesylate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:obatoclax mesylate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  442. en:oblimersen --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:oblimersen | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  443. en:oleandrin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:oleandrin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  444. en:opioid growth factor --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:opioid growth factor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  445. en:oregovomab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:oregovomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  446. en:organic sulfone compound --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:organic sulfone compound | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  447. en:oxphos inhibitor vlx600 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:oxphos inhibitor vlx600 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  448. en:p-cadherin antagonist pf-03732010 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:p-cadherin antagonist pf-03732010 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  449. en:p-cadherin inhibitor pca062 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:p-cadherin inhibitor pca062 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  450. en:p-cadherin-targeting agent pf-06671008 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:p-cadherin-targeting agent pf-06671008 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  451. en:p53-hdm2 interaction inhibitor mi-773 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:p53-hdm2 interaction inhibitor mi-773 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  452. en:p53/hdm2 interaction inhibitor cgm097 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:p53/hdm2 interaction inhibitor cgm097 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  453. en:paclitaxel --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:paclitaxel | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  454. en:panobinostat --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:panobinostat | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  455. en:pbi-shrna stmn1 lipoplex --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pbi-shrna stmn1 lipoplex | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  456. en:pbn derivative okn-007 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pbn derivative okn-007 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  457. en:pembrolizumab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pembrolizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  458. en:penberol --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:penberol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  459. en:pertuzumab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pertuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  460. en:pharmaceutical product-related substance --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pharmaceutical product-related substance | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  461. en:photosensitizing agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:photosensitizing agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  462. en:pomalidomide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pomalidomide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  463. en:pr-104 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pr-104 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  464. en:pre-1938 product --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pre-1938 product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  465. en:procaspase activating compound-1 vo-100 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:procaspase activating compound-1 vo-100 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  466. en:protective agent --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:protective agent | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  467. en:pv-10 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pv-10 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  468. en:pyridyl cyanoguanidine chs 828 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:pyridyl cyanoguanidine chs 828 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  469. en:quarfloxin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:quarfloxin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  470. en:quinacrine hydrochloride --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:quinacrine hydrochloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  471. en:rapid-onset opioid --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:rapid-onset opioid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  472. en:razoxane --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:razoxane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  473. en:realgar-indigo naturalis formulation --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:realgar-indigo naturalis formulation | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  474. en:recombinant ephb4-hsa fusion protein --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:recombinant ephb4-hsa fusion protein | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  475. en:recreational drug --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:recreational drug | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  476. en:ribosome-inactivating protein cy503 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:ribosome-inactivating protein cy503 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  477. en:ruthenium-based transferrin targeting agent nkp-1339 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:ruthenium-based transferrin targeting agent nkp-1339 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  478. en:samarium sm-153 lexidronam pentasodium --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:samarium sm-153 lexidronam pentasodium | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  479. en:sdf-1-targeted agent nox-a12 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sdf-1-targeted agent nox-a12 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  480. en:selinexor --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:selinexor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  481. en:sig12d loder --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sig12d loder | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  482. en:siltuximab --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:siltuximab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  483. en:smac mimetic gdc-0152 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:smac mimetic gdc-0152 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  484. en:smac mimetic gdc-0917 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:smac mimetic gdc-0917 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  485. en:smac mimetic lcl161 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:smac mimetic lcl161 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  486. en:sns01-t nanoparticles --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sns01-t nanoparticles | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  487. en:sodium borocaptate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sodium borocaptate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  488. en:sodium dichloroacetate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sodium dichloroacetate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  489. en:sparfosic acid --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sparfosic acid | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  490. en:sr-t100 gel --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:sr-t100 gel | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  491. en:streptozocin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:streptozocin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  492. en:synthetic antiandrogen --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:synthetic antiandrogen | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  493. en:tazemetostat --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:tazemetostat | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  494. en:teglarinad chloride --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:teglarinad chloride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  495. en:temozolomide --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:temozolomide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  496. en:testolactone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:testolactone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  497. en:thioguanine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:thioguanine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  498. en:thiotepa --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:thiotepa | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  499. en:tilorone --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:tilorone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  500. en:tirapazamine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:tirapazamine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  501. en:topoisomerase-ii inhibitor --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:topoisomerase-ii inhibitor | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  502. en:topsalysin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:topsalysin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  503. en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  504. en:trimetrexate --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:trimetrexate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  505. en:triptorelin --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:triptorelin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  506. en:trpv6 calcium channel inhibitor sor-c13 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:trpv6 calcium channel inhibitor sor-c13 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  507. en:urokinase-derived peptide a6 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:urokinase-derived peptide a6 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  508. en:vegf/hgf-targeting darpin mp0250 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:vegf/hgf-targeting darpin mp0250 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  509. en:venetoclax --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:venetoclax | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  510. en:vinca alkaloid compound --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:vinca alkaloid compound | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  511. en:vincristine --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:vincristine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  512. en:vismodegib --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:vismodegib | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  513. en:vorinostat --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:vorinostat | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  514. en:xanthohumol --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:xanthohumol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  515. en:xiap/ciap1 antagonist astx660 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:xiap/ciap1 antagonist astx660 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  516. en:xpo1 inhibitor kpt-8602 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:xpo1 inhibitor kpt-8602 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  517. en:xpo1 inhibitor sl-801 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:xpo1 inhibitor sl-801 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  518. en:z-360 --- r_associated #0: 20 --> en:antileukemic agent
    n1=en:z-360 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=20
  519. Beurmann et Gougerot (maladie de) --- r_associated #0: 15 --> en:antileukemic agent
    n1=Beurmann et Gougerot (maladie de) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  520. Bussuquara (virus) --- r_associated #0: 15 --> en:antileukemic agent
    n1=Bussuquara (virus) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  521. Carlens (sonde de) --- r_associated #0: 15 --> en:antileukemic agent
    n1=Carlens (sonde de) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  522. ciseaux (marche en) --- r_associated #0: 15 --> en:antileukemic agent
    n1=ciseaux (marche en) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  523. cyclope (oeil) --- r_associated #0: 15 --> en:antileukemic agent
    n1=cyclope (oeil) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  524. en:adversary --- r_associated #0: 15 --> en:antileukemic agent
    n1=en:adversary | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  525. en:medicament --- r_associated #0: 15 --> en:antileukemic agent
    n1=en:medicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  526. en:medicinal product --- r_associated #0: 15 --> en:antileukemic agent
    n1=en:medicinal product | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  527. en:tablet --- r_associated #0: 15 --> en:antileukemic agent
    n1=en:tablet | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  528. fluorescence induite par la tétracycline (test de) --- r_associated #0: 15 --> en:antileukemic agent
    n1=fluorescence induite par la tétracycline (test de) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  529. medicament --- r_associated #0: 15 --> en:antileukemic agent
    n1=medicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  530. médicament --- r_associated #0: 15 --> en:antileukemic agent
    n1=médicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=15
  531. uréthanne --- r_associated #0: 11 --> en:antileukemic agent
    n1=uréthanne | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=11
  532. 5 fluoro-uracile --- r_associated #0: 10 --> en:antileukemic agent
    n1=5 fluoro-uracile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  533. Alicament --- r_associated #0: 10 --> en:antileukemic agent
    n1=Alicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  534. Antimétabolite --- r_associated #0: 10 --> en:antileukemic agent
    n1=Antimétabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  535. Asparaginase --- r_associated #0: 10 --> en:antileukemic agent
    n1=Asparaginase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  536. Busulfan --- r_associated #0: 10 --> en:antileukemic agent
    n1=Busulfan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  537. Cannabidiol --- r_associated #0: 10 --> en:antileukemic agent
    n1=Cannabidiol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  538. Carmustine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Carmustine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  539. Cisplatine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Cisplatine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  540. Cyclophosphamide --- r_associated #0: 10 --> en:antileukemic agent
    n1=Cyclophosphamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  541. Dieck (méthode de) --- r_associated #0: 10 --> en:antileukemic agent
    n1=Dieck (méthode de) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  542. Diéthylstilbestrol --- r_associated #0: 10 --> en:antileukemic agent
    n1=Diéthylstilbestrol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  543. Enzalutamide --- r_associated #0: 10 --> en:antileukemic agent
    n1=Enzalutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  544. Fludarabine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Fludarabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  545. Fluorouracile --- r_associated #0: 10 --> en:antileukemic agent
    n1=Fluorouracile | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  546. Gemcitabine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Gemcitabine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  547. Ipilimumab --- r_associated #0: 10 --> en:antileukemic agent
    n1=Ipilimumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  548. Médicament --- r_associated #0: 10 --> en:antileukemic agent
    n1=Médicament | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  549. Médicament orphelin --- r_associated #0: 10 --> en:antileukemic agent
    n1=Médicament orphelin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  550. Métabolite --- r_associated #0: 10 --> en:antileukemic agent
    n1=Métabolite | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  551. Piroxicam --- r_associated #0: 10 --> en:antileukemic agent
    n1=Piroxicam | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  552. Procarbazine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Procarbazine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  553. Ritter-Lyell (syndrome de) --- r_associated #0: 10 --> en:antileukemic agent
    n1=Ritter-Lyell (syndrome de) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  554. Uréthane --- r_associated #0: 10 --> en:antileukemic agent
    n1=Uréthane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  555. Vinblastine --- r_associated #0: 10 --> en:antileukemic agent
    n1=Vinblastine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  556. agoniste du récepteur A3 de l'adénosine CF102 --- r_associated #0: 10 --> en:antileukemic agent
    n1=agoniste du récepteur A3 de l'adénosine CF102 | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  557. alemtuzumab --- r_associated #0: 10 --> en:antileukemic agent
    n1=alemtuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  558. anti-androgène --- r_associated #0: 10 --> en:antileukemic agent
    n1=anti-androgène | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  559. anticorps irrégulier --- r_associated #0: 10 --> en:antileukemic agent
    n1=anticorps irrégulier | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  560. blinatumomab --- r_associated #0: 10 --> en:antileukemic agent
    n1=blinatumomab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  561. butyryl-coenzyme A-déshydrogénase --- r_associated #0: 10 --> en:antileukemic agent
    n1=butyryl-coenzyme A-déshydrogénase | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  562. camptothécine --- r_associated #0: 10 --> en:antileukemic agent
    n1=camptothécine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  563. chlorambucil --- r_associated #0: 10 --> en:antileukemic agent
    n1=chlorambucil | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  564. composé organique de sulfone --- r_associated #0: 10 --> en:antileukemic agent
    n1=composé organique de sulfone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  565. dacarbazine --- r_associated #0: 10 --> en:antileukemic agent
    n1=dacarbazine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  566. daratumumab --- r_associated #0: 10 --> en:antileukemic agent
    n1=daratumumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  567. diffusant --- r_associated #0: 10 --> en:antileukemic agent
    n1=diffusant | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  568. diméthylsulfoxyde --- r_associated #0: 10 --> en:antileukemic agent
    n1=diméthylsulfoxyde | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  569. en:Carlens' tube --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:Carlens' tube | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  570. en:busulphan. --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:busulphan. | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  571. en:cyclops eye --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:cyclops eye | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  572. en:enemy --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:enemy | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  573. en:medicine --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:medicine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  574. en:nutriceutical --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:nutriceutical | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  575. en:pill --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:pill | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  576. en:scissors gait --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:scissors gait | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  577. en:sparring partner --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:sparring partner | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  578. en:tetracyclin-induced fluorescence test --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:tetracyclin-induced fluorescence test | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  579. en:type of endotracheal tube with two lumens --- r_associated #0: 10 --> en:antileukemic agent
    n1=en:type of endotracheal tube with two lumens | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  580. facteur disruptif --- r_associated #0: 10 --> en:antileukemic agent
    n1=facteur disruptif | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  581. facteur déterminant de changement --- r_associated #0: 10 --> en:antileukemic agent
    n1=facteur déterminant de changement | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  582. floxuridine --- r_associated #0: 10 --> en:antileukemic agent
    n1=floxuridine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  583. flutamide --- r_associated #0: 10 --> en:antileukemic agent
    n1=flutamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  584. ifosfamide --- r_associated #0: 10 --> en:antileukemic agent
    n1=ifosfamide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  585. imiquimod --- r_associated #0: 10 --> en:antileukemic agent
    n1=imiquimod | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  586. lomustine --- r_associated #0: 10 --> en:antileukemic agent
    n1=lomustine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  587. melphalan --- r_associated #0: 10 --> en:antileukemic agent
    n1=melphalan | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  588. mitoxantrone --- r_associated #0: 10 --> en:antileukemic agent
    n1=mitoxantrone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  589. médicament (contrôle du) --- r_associated #0: 10 --> en:antileukemic agent
    n1=médicament (contrôle du) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  590. médicaments --- r_associated #0: 10 --> en:antileukemic agent
    n1=médicaments | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  591. méthotrexate --- r_associated #0: 10 --> en:antileukemic agent
    n1=méthotrexate | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  592. oléandrine --- r_associated #0: 10 --> en:antileukemic agent
    n1=oléandrine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  593. opposante --- r_associated #0: 10 --> en:antileukemic agent
    n1=opposante | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  594. pembrolizumab --- r_associated #0: 10 --> en:antileukemic agent
    n1=pembrolizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  595. pertuzumab --- r_associated #0: 10 --> en:antileukemic agent
    n1=pertuzumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  596. prémédication --- r_associated #0: 10 --> en:antileukemic agent
    n1=prémédication | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  597. révolution technologique --- r_associated #0: 10 --> en:antileukemic agent
    n1=révolution technologique | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  598. siltuximab --- r_associated #0: 10 --> en:antileukemic agent
    n1=siltuximab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  599. substance additive --- r_associated #0: 10 --> en:antileukemic agent
    n1=substance additive | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  600. thioguanine --- r_associated #0: 10 --> en:antileukemic agent
    n1=thioguanine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  601. vincristine --- r_associated #0: 10 --> en:antileukemic agent
    n1=vincristine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  602. éflornithine --- r_associated #0: 10 --> en:antileukemic agent
    n1=éflornithine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  603. étoposide --- r_associated #0: 10 --> en:antileukemic agent
    n1=étoposide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=10
  604. BVT --- r_associated #0: 5 --> en:antileukemic agent
    n1=BVT | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  605. Bevacizumab --- r_associated #0: 5 --> en:antileukemic agent
    n1=Bevacizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  606. Finastéride --- r_associated #0: 5 --> en:antileukemic agent
    n1=Finastéride | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  607. Rituximab --- r_associated #0: 5 --> en:antileukemic agent
    n1=Rituximab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  608. alloxane --- r_associated #0: 5 --> en:antileukemic agent
    n1=alloxane | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  609. butanol --- r_associated #0: 5 --> en:antileukemic agent
    n1=butanol | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  610. butanol extractible iodine --- r_associated #0: 5 --> en:antileukemic agent
    n1=butanol extractible iodine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  611. butoconazole --- r_associated #0: 5 --> en:antileukemic agent
    n1=butoconazole | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  612. butyrobétaïne --- r_associated #0: 5 --> en:antileukemic agent
    n1=butyrobétaïne | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  613. butyrophénone --- r_associated #0: 5 --> en:antileukemic agent
    n1=butyrophénone | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  614. butyryl-coenzyme A --- r_associated #0: 5 --> en:antileukemic agent
    n1=butyryl-coenzyme A | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  615. butée de hanche --- r_associated #0: 5 --> en:antileukemic agent
    n1=butée de hanche | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  616. butée de l'épaule --- r_associated #0: 5 --> en:antileukemic agent
    n1=butée de l'épaule | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  617. butée osseuse --- r_associated #0: 5 --> en:antileukemic agent
    n1=butée osseuse | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  618. carnet de santé --- r_associated #0: 5 --> en:antileukemic agent
    n1=carnet de santé | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  619. carnet de soins --- r_associated #0: 5 --> en:antileukemic agent
    n1=carnet de soins | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  620. cladribine --- r_associated #0: 5 --> en:antileukemic agent
    n1=cladribine | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  621. cyanure de mercure --- r_associated #0: 5 --> en:antileukemic agent
    n1=cyanure de mercure | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  622. cyclopeptide --- r_associated #0: 5 --> en:antileukemic agent
    n1=cyclopeptide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  623. cyclophiline --- r_associated #0: 5 --> en:antileukemic agent
    n1=cyclophiline | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  624. cyclophorie --- r_associated #0: 5 --> en:antileukemic agent
    n1=cyclophorie | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  625. en:sarcolysin --- r_associated #0: 5 --> en:antileukemic agent
    n1=en:sarcolysin | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  626. fluoro --- r_associated #0: 5 --> en:antileukemic agent
    n1=fluoro | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  627. hormones antinéoplasiques --- r_associated #0: 5 --> en:antileukemic agent
    n1=hormones antinéoplasiques | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  628. maladie de Beurmann et Gougerot --- r_associated #0: 5 --> en:antileukemic agent
    n1=maladie de Beurmann et Gougerot | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  629. syndrome de Butler-Albright --- r_associated #0: 5 --> en:antileukemic agent
    n1=syndrome de Butler-Albright | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  630. villeuse de la vessie (maladie) --- r_associated #0: 5 --> en:antileukemic agent
    n1=villeuse de la vessie (maladie) | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
  631. Élément déclencheur --- r_associated #0: 5 --> en:antileukemic agent
    n1=Élément déclencheur | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr